CVCT

December 7 - 9, 2026
The Mayflower Hotel, Washington DC



SCIENTIFIC PROGRAM

23rd Global Cardio Vascular Clinical Trialists Forum

MONDAY, DECEMBER 7TH

PALM COURT

8:30 - 10:30	10:30 - 11:00	11:00 - 13:00	13:00 - 14:00	14:00 - 16:00	16:00 - 16:30	16:30 - 19:00
LDL CHOLESTEROL view details >>		LP (A) TRIALS view details >>		LBCT 2 view details >>		CELL THERAPY view details >>

EAST

8:30 - 10:30	10:30 - 11:00	11:00 - 13:00	13:00 - 14:00	14:00 - 16:00	16:00 - 16:30	16:30 - 19:30
AMYLOIDOSIS view details >>		HYPERTROPHIC CARDIOMYOPATHY view details >>		PATIENT-REPORTED OUTCOMES view details >>		HYPERTENSION view details >>

STATE

8:30 - 10:30	10:30 - 11:00	11:00 - 13:00	13:00 - 14:00	14:00 - 16:00	16:00 - 16:30	16:30 - 19:30
ALDOSTERONE IN CKM view details >>		CKM TRIALS view details >>		WOMEN'S HEALTH view details >>		RISK OF ASCVD view details >>

BALLROOM

8:30 - 10:30	10:30 - 11:00	11:00 - 13:00	13:00 - 14:00	14:00 - 16:00	16:00 - 16:30	16:30 - 19:30
AI MASTER CLASS 1 view details >>		AI MASTER CLASS 2 view details >>		iCVCT #5 MEDTECH STARTUPS view details >>		BIOTECH STARTUPS view details >>

CHINESE

11:00 - 13:00	16:30 - 19:30
LBCT 1 view details >>	PATIENT SESSION view details >>

19:30 - 21:00 CVCT RECEPTION

TUESDAY, DECEMBER 8TH

PALM COURT

8:30 - 10:30	10:30 - 11:00	11:00 - 13:00	13:00 - 13:30	14:30 - 16:30	16:30 - 17:00	17:00 - 19:00
iCVCT #1 THROMBOSIS view details >>		INDUSTRY-ACADEMIA INTERACTIONS view details >>		OBESITY NEW DATA view details >>		OBESITY: BODY COMPOSITION view details >>

EAST

8:30 - 10:30	10:30 - 11:00	11:00 - 13:00	13:00 - 13:30	14:30 - 16:30	16:30 - 17:00	17:00 - 19:00
ZEUS DEEP DIVE view details >>		ANTI-INFLAMMATORY & ASCVD view details >>		PAH 1 view details >>		GREAT DEBATES view details >>

13.30 - 14.20: KEYNOTE LECTURE by Marc Pfeffer (Boston, MA, USA) & Victor J. Dzau (Boston, MA, USA)

STATE

8:30 - 10:30	10:30 - 11:00	11:00 - 13:00	13:00 - 13:30	14:30 - 16:30	16:30 - 17:00	17:00 - 19:00
STATS MASTERCLASS # 1 view details >>		iCVCT #2 VENTRICULAR ASSIST DEVICES view details >>		iCVCT # 3 IMPLANTABLES FOR DENOVO PCI view details >>		iCVCT #4 VALVE TRIALS view details >>

BALLROOM

8:30 - 10:30	10:30 - 11:00	11:00 - 13:00	13:00 - 13:30	14:30 - 16:30
AI MASTER CLASS 4 view details >>		STATS MASTERCLASS #2 view details >>		STATS MASTERCLASS #3 view details >>

CHINESE

11:00 - 13:00	13:00 - 13:30	14:30 - 16:30	16:30 - 17:00	17:00 - 19:00
LBCT 3 view details >>		LBCT 4 view details >>		PAH 2 view details >>

19:00 - 21:00
RECEPTION CVCT AWARDS CEREMONY

WEDNESDAY, DECEMBER 9TH

PALM COURT

8:00 - 10:00	10:00 - 10:30	10:30 - 13:30	13:30 - 14:30	14:30 - 16:30
GENE THERAPY view details >>		GENETIC MEDICINE view details >>		EP STROKE view details >>



EAST

8:00 - 10:00	10:00 - 10:30	10:30 - 13:30	13:30 - 14:30	14:30 - 16:30
HF MEETS EP view details >>		CHRONIC HEART FAILURE DEVICES view details >>		IMPLEMENTATION SCIENCE AND PAYMENT REFORM view details >>



STATE

8:00 - 10:00	10:00 - 10:30	10:30 - 13:30	13:30 - 14:30	14:30 - 16:00
IMPLEMENTATION view details >>		WEARABLES view details >>		DRIVERS OF HEART FAILURE view details >>



BALLROOM

8:00 - 10:00	10:00 - 10:30	10:30 - 13:30	13:30 - 14:30	14:30 - 16:30
WHO IS IN THE COMMAND ROOM? view details >>		TRIALS' PUBLISHING & ADOPTION view details >>		REGULATORY HARMONIZATION view details >>



CHINESE

10:30 - 13:30
LBCT 5 view details >>

FACULTY

ACADEMY

1. William Abraham (Columbus, OH, USA)
2. Rahul Aggarwal (Boston, MA, USA)
3. Gorav Ailawadi (Ann Arbor, MI, USA)
4. Alberto Aimo (Pisa, IT)
5. Ziad Ali (New York, NY, USA)
6. Jason Andrade (Vancouver, BC, CAN)
7. Alessia Argirò (Florence, ITA)
8. Suzanne Arnold (Kansas City, MO, USA)
9. Garima Arora (Birmingham, AL, USA)
10. Clare Arnott (Sydney, AU)
11. Deborah Ascheim (Boston, MA, USA)
12. Michel Azizi (Paris, FRA)
13. Andrew Baker (Edinburgh, GBR)
14. Suzanne Baron (Boston, MA, USA)
15. Tina Baykaner (Stanford, CA, USA)
16. Ankeet S. Bhatt (San Francisco, CA, USA)
17. Jan Biegus (Wrocław, POL)
18. Erin Bohula (Boston, MA, USA)
19. Biykem Bozkurt (Houston, TX, USA)
20. Jenifer Brown (Boston, MA, USA)
21. Dan Burkhoff (New York, NY, USA)
22. Javed Butler (Dallas, TX, USA)
23. Robert Califf (Durham, NC, USA)
24. Francesco Cappelli (Florence, ITA)
25. Ediina Cenko (Bologna, IT)
26. Antonio Ceriello (Milan,ITA)
27. Rishi Chandiramani (Baltimore, USA)
28. Kelly Chin (Dallas, TX, USA)
29. Leslie Cho (Cleveland, OH, USA)
30. Clara Chow (Sydney, AUS)
31. Brian Claggett (Boston, MA, USA)
32. Caroline Coats (Glasgow, GBR)
33. David Cohen (Boston, MA, USA)
34. Roisin Colleran (Galway, IRL)
35. Maria Rosa Costanzo (Naperville, IL, USA)
36. Jonathan Cunningham (Boston, MA, USA)
37. Donald Cutlip (Boston, MA, USA)
38. Issa Dahabreh (Boston, MA, USA)
39. Zainab Dakhil (Baghdad, IRA)
40. John Deanfield (London, GBR)
41. Lovedeep Dhingra (New Haven, CT, USA)
42. Ron Do (New York, NY, USA)
43. Kieran Docherty (Glasgow, GBR)
44. Jessilyn Dunn (Durham, NC, USA)
45. Victor J. Dzau (Boston, MA, USA)
46. Perry Elliott (London, GBR)
47. Mariam Elmegaard (Herlev, DEN),
48. Anthony Etyang (Kilifi, KEN)
49. Hap Farber (Boston, MA, USA)
50. Naomi Fisher (Boston, MA, USA)
51. Mona Fiuzat (Washington, DC, USA)
52. Mariana Fontana (London, UK)
53. Marat Fudim (Durham, NC, USA)
54. Valentin Fuster (New York, NY, USA)
55. Praktiki Gaba (Boston, MA, USA)
56. Karen Gainey (Sydney, AUS)
57. Habib Gamra (Sousse, TUN)
58. Philippe Garot (CERC, FRA)
59. Michael Gibson (Boston, MA, USA)
60. Jason Gill (Glasgow, GBR)
61. Nicolas Girerd (Nancy, FRA)
62. Mardi Gomberg-Maitland (Washington, DC, USA)
63. Sascha Goonewardena (Ann Arbor, MI, USA)
64. Martha Gulati (Los Angeles, CA, USA)
65. Aakriti Gupta (New York, NY, USA)
66. Edip Gurol (Boston, MA, USA)
67. Juan Granada (New York, NY, USA)
68. Christopher Granger (Durham, NC, USA)
69. Jennifer Green (Durham, NC, USA)
70. Barry Greenberg (San Diego, CA, USA)
71. Bernard Gersh (Rochester, MN, USA)
72. Justin Grodin (Dallas, TX, USA)
73. Roger Hajjar (Boston, MA, USA)
74. Frank Harrell (Nashville, TN, USA)
75. Josephine Harrington (Denver, COL)
76. Anna Hemnes (Nashville, TN, USA)
77. Hiddo Heerspink (Groningen, NED)
78. Miguel Hernán (Boston, MA, USA)
79. Adrian Hernandez (Durham, NC, USA)
80. Will Herrington (Oxford, GBR)
81. Nick Hill (Boston, MA, USA)
82. Mark Huffman (St Louis, MO, USA)
83. Marc Humbert (Paris, FRA)
84. Riccardo Inciardi (Brescia, IT)
85. Kiyotake Ishikawa (New York, NY, USA)
86. Dhruv Kazi (Boston, MA, USA)
87. Sanjay Kaul (Los Angeles, CA, USA)

88. Steve Kawut (Philadelphia, PA, USA)
89. Shahzeb Khan (Dallas, TX, USA)
90. Rohan Khera (New Haven, CT, USA),
91. Paulus Kirchhof (Hamburg, GER)
92. Masatake Kobayashi (Tokyo, JPN)
93. Wolfgang Koenig (Munich, GER)
94. Mitch Krucoff (Durham, NC, USA)
95. Christine Kupchik (Colorado, CO, USA) Christina Lalani (Boston, MA, USA)
96. Carolyn Lam (Singapore, SGP)
97. Martin Landray (Oxford, GBR)
98. Patrick Lawler (Montreal, CAN)
99. Martin Leon (New York, NY, USA)
100. Klaus Ley (Augusta, GA, USA)
101. Peter Libby (Boston, MA, USA)
102. Jennifer Linge (Linköping, SWE)
103. Ildi Lingvay (Dallas, TX, USA)
104. Sheldon Litwin (Charleston, SC, USA)
105. Giovanna Liuzzo (Rome, ITA)
106. Lars Lund (Stockholm, SWE)
107. Michael Mack (Dallas, TX, USA)
108. Karen Joynt Maddox (St. Louis, MO, USA)
109. Ken Mahaffey (Stanford, CA, USA)
110. John Mandrola (Louisville, KY, USA)
111. Eduardo Marban (Los Angeles, CA, USA)
112. Maritza McIntyre (Advanced Therapies Partners, MD, USA)
113. Martin Maron (Boston, MA, USA)
114. James Martin (Dallas, TX, USA)
115. Ahmad Masri (Portland, OR, USA)
116. Preston Mason (Boston, MA, USA),
117. Manuel Mayr (London, GBR)
118. Darren McGuire (Dallas, TX, USA)
119. Vallerie McLaughlin (Ann Arbor, MI, USA)
120. Calum Mac Rae (Boston, MA, USA)
121. Alexandre Mebazaa (Paris, FRA)
122. Mandeep Mehra (Boston, MA, USA)
123. Roxana Mehran (New York, NY, USA)
124. Philippe Menasché (Paris, FRA)
125. Guiomar Mendieta-Badimon (Barcelona, ESP)
126. Robert Mentz (Durham, NC, USA)
127. Javier Morales (New York, N, USA)
128. Pamela Morris (Mount Pleasant, SC, USA)
129. Paul Muntner (Birmingham, AL, USA)
130. Ann Marie Navar (Dallas, TX, USA)
131. Steven Nathan (Falls Church, VA, USA)
132. Steven Nissen (Cleveland, OH, USA)
133. Brendon Neuen (Sydney, AUS)
134. Borge Nordestgaard (Copenhagen, DNK)
135. Nick Nurmohamed (Amsterdam, NED)
136. Mpiko Ntsekhe (Cape Town, SA)
137. Christopher O'Connor (Washington, DC, USA)
138. Michelle O'Donoghue (Boston, MA, USA)
139. Evangelos K Oikonomou (New Haven, CT, USA)
140. Joanna Osmanska (Glasgow, UK)
141. Iacopo Olivotto (Florence, ITA)
142. Anjali Owens (Philadelphia, PA, USA)
143. Neha Pagidipati (Durham, NC, USA)
144. Milton Packer (Dallas, TX, USA)
145. Ambarish Pandey (Dallas, TX, USA)
146. Victoria Parikh (Stanford, CA, USA)
147. Aline Pedroso (San Francisco,CA, USA)
148. Emerson Perin (Houston, TX, USA)
149. Divaka Perera (London, GBR)
150. Mark Petrie (Glasgow, GBR)
151. Marc Pfeffer (Boston, MA, USA)
152. Bertram Pitt (Ann Arbor, MI, USA)
153. Jorge Plutzky (Boston, MA, USA)
154. Jeffrey Popma (CRF, USA)
155. Iona Preston (Boston, MA, USA)
156. Silvia Priori (Pavia, ITA)
157. Odayme Quesada (Cincinnati, OH, USA)
158. Rita Redberg (San Francisco, CA, USA)
159. Yogesh Reddy (Rochester, MN, USA)
160. Frederic Resnic (Burlington, MA, USA)
161. Paul Ridker (Boston, MA, USA)
162. Stuart Rich (Chicago, IL, USA)
163. Frank Rockhold (Durham, NC, USA)
164. Anthony Rodgers (Sydney, AUS)
165. Blanca Rodriguez (Oxford, GBR)
166. Lindsey Rosman (Chicago, IL, USA)
167. Robert Rosenson (New York, NY, USA)
168. Joseph Rossano (Philadelphia, PA, USA)
169. Anne-Christine Ruwald (Copenhagen, DK)
170. Marc Sabatine (Boston, MA, USA)
171. Naveed Sattar (Glasgow, GBR)
172. Sandeep Sahay (Houston, TX, USA)
173. Mohan Sailesh (New Delhi, IND)
174. Gianluigi Savarese (Stockholm, SWE)
175. Ben Saville (Austin, TX, USA)
176. Markus Schlaich (Perth, AUS)
177. Roland Schmieder (Erlangen, GER)
178. Greg Schwartz (Denver, CO, USA)
179. Sebastian Schneeweiss (Boston, MA, USA)
180. Michele Senni (Bergamo, ITA)
181. Nishant Shah (Durham, NC, USA)
182. Abhinav Sharma (Montreal, CAN)
183. Mike Sharma (Hamilton, ON, CAN)
184. Oksana Shlobin (Falls Church, VA, USA)
185. Chrisandra L. Shufelt (Jacksonville, FL, USA)
186. Tabassome Simon (Paris, FRA)
187. Olivier Sitbon (Paris, FRA)

188. Hicham Skali (Boston, MA, USA)
189. Christian Sohns (Hannover, GER)
190. Scott Solomon (Boston, MA, USA)
191. Tor Beiring Sorensen (Copenhagen, DK)
192. John Spertus (Kansas City, MO, USA)
193. Rouchelle Sriranjan-Rothwell (Cambridge, GBR)
194. Gregg Stone (New York, NY, USA)
195. Aijun Sun (Shanghai, CN)
196. Emma Svennberg (Stockholm, SWE)
197. Ibrahim Halil Tanboga (Istanbul, TUR)
198. Jean Claude Tardif (Montreal, CAN)
199. Pam Taub (San Diego, CA, USA)
200. John Teerlink (San Francisco, CA, USA)
201. Vinod Thourani (Atlanta, GA, USA)
202. Thomas Thum (Hannover, GER)
203. Jan Tijssen (Brussels, BEL)
204. Lale Tokgozoglu (Ankara, TUR)
205. Mark Toshner (Cambridge, GBR)
206. Rhian Touyz (Montreal, CAN)
207. Mintu Turakhia (Stanford, CA, USA)
208. Harriette Van Spall (Hamilton, CAN)
209. Jean-Luc Vachiéry (Brussels, BEL)
210. Anjali Vaidya (Philadelphia, PA, USA)
211. Muthiah Vaduganathan (Boston, MA, USA)
212. Frances Varian (Sheffield, GBR),
213. Sreek Vemulapalli (Durham, NC, USA)
214. Corey Ventetuolo (Providence, RI, USA)
215. Stefan Verheye (Brussels, BEL)
216. Atul Verma (Hamilton, CAN)
217. Subodh Verma (Toronto, CAN)
218. Milos Vukadinovic (Los Angeles, CA, USA)
219. Rishi Wadhera (Boston, MA, USA)
220. Ron Waksman (Washington, DC, USA)
221. Paul Wang (Stanford, CA, USA)
222. Lynne Warner Stevenson (Nashville, TN, USA)
223. Oussama Wazni (Cleveland, OH, USA)
224. Jason Weatherald (Edmonton, CA)
225. Jeffrey Weitz (Hamilton, CAN)
226. Bryan Williams (London, GBR)
227. Seppo Ylä-Herttuala (Kuopio, FIN)
228. Robert Yeh (Boston, MA, USA)
229. Morag Young (Melbourne, AUS)
230. Faiez Zannad (Paris, FRA)
231. Andre Zimerman (Porto Alegre, BRA)

INDUSTRY

232. Phillip Adamson (CVRx, USA)
233. Hafid Ait Oufella (Polygon, FRA)
234. David Albert (AliveCor, USA)
235. Yousuf Ali (Boehringer Ingelheim, GER)
236. Dom Alloco (Shockwave/J&J, USA)
237. Peter Altman (BioCardia, USA)
238. Greg Aubert (Lexeo Therapeutics, USA)
239. Laurent Audoly (PriveBio, USA)
240. Michael Ayers (Edgewise, USA),
241. Puja Banka (Merck, Rahway, USA)
242. Sameer Bansilal (Alnylam, USA)
243. Arnaud Bastien (BMS, USA)
244. David Bauman (Schrodinger, USA)
245. Scott Berry (Berry Consultants, USA)
246. Narinder Bhalla (Lexeo Therapeutics, USA)
247. Robert Blaustein (Immutrin, USA)
248. Juuso Blomster (CardioSignal, FIN),
249. Alexander Blood (AlwithCare, USA)
250. Antonieta Bomfim (Boehringer Ingelheim, GER)
251. Maria Borentain (Bayer, GER)
252. Meike Brinker (Bayer, GER)
253. Martina Brueckmann (Roche, CH)
254. Gabriel Brooks (Solid Biosciences, USA)
255. Brieana Buckley (Editas,Medicine, USA)
256. Chris Cabell (Inhibikase, USA)
257. Hui Cao (Novartis, USA)
258. Rafael Cavalcante (Boston Scientific, USA)
259. Shon Chakrabarti (Recor Medical, USA),
260. Jersey Chen (Lilly, USA)
261. Jeff Closs (Ancora, USA)
262. Martine Clozel (Idorsia, CHE)
263. Kevin Costa (Novoheart, USA)
264. Amy Crawford (Berry Consultants, USA)
265. Graziella Collu (AstraZeneca, USA)
266. Bjorn Dahlof (Cereno, SWE)
267. Alex DePaoli (Rona Therapeutics, CHN)
268. Jason Duran (CRISPR Therapeutics, USA)
269. Punag Divanji (Cytokinetics, USA)
270. Jay Edelberg (Kardigan, USA)
271. Marc Evanchik (BraveHeart Bio, USA)
272. Jennifer Hellawell (Arrowhead pharmaceuticals, USA)
273. Mads Engelmann (NovoNordisk, DEN)
274. Odd Erik (Roche, CH)
275. Chris Farina (Abcentra, USA)
276. Sergio Fazio (Corsera, USA)
277. Udi Fainberg (Novo Nordisk, DK)
278. Juan Camilo Arjona Ferreira (Organon, COL)
279. Amy Ford (Lilly, USA)
280. Folke Folkvaljon (AstraZeneca, ESP)
281. Kristen Fortney (BioAge, USA)
282. Jonathan Fox (BridgeBio, USA)
283. Keiichi Fukuda (Heartseed, JPN)
284. Anders Gabrielsen (Ribocure, SWE),
285. Christine Garrett (Preload Therapeutics)

286. Federica Genovese (Nordic Bioscience, DNK)
287. Jyothis George (Rezera, GBR)
288. Justin Godown (Cytokinetics, USA)
289. Sofia Gerward (Novo Nordisk, USA)
290. Alexandra Goncalves (BMS, USA),
291. Nick Gossen (Dandelion, USA)
292. Christine Guo (Ametris, USA)
293. Kendra Grubb (Medtronic, USA)
294. András Gruber (Aronora, USA)
295. Finn Gustafsson (Abbott, USA)
296. David Gutstein (Regeneron, USA),
297. Steve Heitner (Cytokinetics, USA),
298. Graeme Hickey (Medtronic, USA)
299. Udo Hoffmann (Cleerly / MGH, USA)
300. Silviu Itescu (Mesoblast, AUS)
301. Filip Janku (Monterosa, USA)
302. Vinny Jindal (Secretome Tx, USA)
303. Per Johannsen (AstraZeneca, SWE)
304. Amer Joseph (Idorsia, CHE),
305. Faouzi Kallel (Berlin Heals, GER),
306. Navin Kapur (Abiomed/JnJ, USA)
307. Rob Kazmierski (MCRA, USA)
308. Sekar Kathiresan (Verve, USA)
309. Amit Khera (Verve Therapeutics, USA)
310. James Kim (Medera, USA)
311. So Young Kim (Tenax, USA)
312. Filip Knop (NovoNordisk, DNK)
313. Mikhail Kosiborod (AstraZeneca, USA)
314. John Laschinger (Edwards, USA),
315. Charles Lee (AstraZeneca, USA)
316. Anastasia Lesogor (Novartis, CHE)
317. Howard Levin (Coridea, USA)
318. Dustin Little (Nuvectis Pharma, Inc, USA)
319. Jonathan Lu (Alexion, USA)
320. Steve Lubitz (Novartis, USA)
321. Craig Markovitz (Magenta Medical, ISR)
322. Peter Erland Marstrand (NovoNordisk, DNK)
323. Greg Michaud (JnJ, USA)
324. Eva Muehlhofer (Bayer, GER)
325. Gillian Murtagh (Bridgebio, USA)
326. Shahid Nimjee (Basking Biosciences, USA)
327. Richard Nkulikiyinka (GenKardia, USA)
328. Chris O`Donnell (Novartis, CH)
329. Bakul Patel (Google, USA)
330. Nirav Patel (Medtronic, USA)
331. Mahesh Patel (Merck, USA)
332. Natasha Paterson (Tenaya Therapeutics, USA)
333. Shira Perl (AstraZeneca, USA)
334. Emmanuelle Pham (NovoInSilico, FRA)
335. Garrett Pilcher (Medtronic, USA)
336. Heng Tony Qian (Olink, USA)
337. Christina Quarta (Alexion, USA)
338. Franck Rahaghi (United Therapeutics, USA)
339. Mark Reisman (Edwards, USA)
340. Manju Revanna (NovoNordisk, DNK)
341. Marzia Rigolli (Eli Lilly, USA)
342. Benjamin Rosand (Cleo Health, USA)
343. Maria Sejersten Ripa (Novo Nordisk, DNK)
344. Luke Roberts (Bayer, GER)
345. Lothar Roessig (AskBio, GER)
346. Campbell Rogers (Heartflow, USA)
347. Katja Rohwedder (Bayer, GER)
348. Nitin Salunke (Supira Medical, USA)
349. Carlos Sanmarco (Pulmovant, USA)
350. Patrick Schlömer (BAYER, GER),
351. Monica Shah (Nuevocor, SGP)
352. Motasim Sirhan (Elixir Medical, USA)
353. Stanko Skrtic (HeartBeat.bio, AUT)
354. Derek Solum (United Therapeutics, USA),
355. Simon Sonntag (Virtonomy, GER)
356. Luba Soskin (Bayer, CHE)
357. Evan Stein (Lib Therapeutix, USA),
358. Kenneth Stein (Boston Scientific, USA)
359. Norman Stockbridge (S&S Consulting, USA)
360. Kate Stohlman (Corvia, USA)
361. Howard Surks (Cardurion, USA)
362. Whit Tingley (Tenaya Therapeutics, USA)
363. Sam Tsimikas (Ionis, USA)
364. Alessia Urbinati (Merck, USA)
365. Liron Walsh (Intellia, USA)
366. Eugene Wang (HELP Therapeutics, CHN)
367. Janet Wittes (Wittes LLC, USA)
368. Stephen Wiviott (AstraZeneca, USA)
369. Dion Zappe (Alnylam, USA)
370. Cordula Zeller (Boehringer Ingelheim, GER)
371. Jie Zeng (Rona Therapeutics, CHN)
372. Rainer Zimmermann (Gossamer, USA)

NIH / NHLBI / Government

373. Janine Clayton (NIH/ OWH, USA)
374. Patrice Desvigne-Nickens (NIH/NHLBI, USA)
375. Laurie Donze (NIH/NHLBI, USA)
376. Kathleen Fenton (NHLBI, USA)
377. Tomasz Guzik (National Heart and Lung Institute, GBR),
378. Cara Lewis (NIH/NHLBI, USA)
379. Eric Leifer (NIH/NHLBI, USA)
380. George Mensah (NIH/NHLBI, USA)

REGULATORY

381. Rick Abramson (FDA, USA)
382. Tariq Ahmad (FDA, USA)
383. Stephen Browning (FDA, USA)
384. Eileen Craig (FDA, USA)
385. Chad Kliger (FDA, USA)
386. Aneesh Deoras (FDA, USA)
387. Charu Gandotra (FDA, USA)
388. Jacob George (MHRA, GBR)
389. Lydia Glaw (FDA, USA)
390. William Herzog (FDA, USA)
391. Manabu Inoue (PDMA, JPN)
392. Alar Irs (EMA, EST)
393. Akihiro Ishiguro (PMDA, Tokyo, JPN)
394. Megha Kaushal (FDA, USA)
395. Mori Krantz (FDA, USA)
396. Tzu-Yun.McDowell (FDA, USA)
397. April Marrone (FDA, USA)
398. Karim Mikhail (FDA, USA)
399. Chinwe Okoro (FDA, USA)
400. Rachel Neubrander (FDA, USA)
401. Ileana Pinea (FDA, USA)
402. Lisa Plummer (FDA, USA)
403. Jordan Pomeroy (FDA, USA)
404. Mitch Psotka (FDA, USA)
405. Ann Punnoose (FDA, USA)
406. Jon Resar (FDA, USA),
407. Kimberly Selzman (FDA, USA)
408. Fortunato Senatore (FDA, USA)
409. Raymond Soccio (FDA, USA)
410. Lawrence Tallon (MHRA, GBR)
411. Aliza Thompson (FDA, USA)
412. Shannon Thor (FDA, USA)
413. James Travis (FDA, USA)
414. Kaveeta Vasisht (FDA, USA)
415. Changfu Wu (FDA, USA)
416. Bram Zuckerman (FDA, USA)

PAYERS / INVESTORS

417. JoAnna Baldwin (CMS, USA)
418. Lee Fleisher (Rubrum Advising, USA)
419. Viral Gandhi (Aviga Health, USA)
420. Hanson Gifford (The Foundry, USA)
421. Craig Gordon (GordonMD Global Investment LP, USA)
422. Dora Hughes (CMS, USA)
423. Marco Marchetti (AGENAS, IT)
424. Jaime Murillo (Bogotá, COL)
425. David Rosenthal (Alleycorp , USA)

JOURNAL

426. Michael Basson (Nature, USA)
427. Kirsten Bibbins-Domingo (JAMA, USA)
428. Flavia Geraldes (The Lancet, GBR)
429. Harlan Krumholz (JACC, USA)
430. Bonnie Ky (JACC Oncology, USA)
431. Jane Leopold (NEJM, USA)
432. Bradley Maron (Circulation, USA)

PATIENTS

433. Marc Bains (HeartLife, CAN)
434. Bray Patrick-Lake (Evidation, USA)
435. Coleen Brunetti (Pulmonary Hypertension Association, USA)
436. Magdalena Daccord (FH Europe Foundation, CHE)
437. Hyvelle Ferguson-Davis (Heart Sistas, USA)
438. ShantaQuilette Carter (Pink Peppermint Project, USA)
439. Patrick Gee (iAdvocate, USA)
440. Pieter Glijnis (Phospholamban Foundation, NED)
441. Celina Gorre (WomenHeart, USA)
442. Corinne Hudson (Pumping Marvellous, GBR)
443. Trudie Lobban (London, GBR)
444. Steven Macari (AVEC, FRA),
445. Francesca Musso (HCM Patient, ITA)
446. Rhonda Monroe (Charlotte, NC, USA)
447. Joseph Nadglowski (Obesity Action Coalition, USA)
448. Lisa Salberg (HCMA, USA)
449. Ratna Devi (DakshamA Health, IND)

Palm court
Monday, December 7, 2026
08:30 -10:30

STRATEGIES TO ACHIEVE LDL CHOLESTEROL GOALS MORE EFFECTIVELY AND MORE EFFICIENTLY
Chairpersons: Pamela Morris (Mount Pleasant, SC, USA) & Greg Schwartz (Denver, CO, USA)

Bivalent approaches to achieve LDL cholesterol goals. Building the platform on a PCSK9 inhibitor
Jie Zeng (Rona Therapeutics, CHN)

Oral combinations getting to goal more effectively – trial design considerations for dual targets
Neha Pagidipati (Durham, NC, USA)

Investigating durable solutions with gene/base editing
Sekar Kathiresan (Verve, USA)

Industry viewpoints
Puja Banka (Merck, USA), Alex DePaoli (Rona Therapeutics, CHN), Jason Duran (CRISPR Therapeutics, USA), Jennifer Hellawell (Arrowhead pharmaceuticals, USA), Per Johannsen (AstraZeneca, SWE), Anastasia Lesogor (Novartis, CHE); Evan Stein (Lib Therapeutix, USA),

Regulatory viewpoint
Eileen Craig (FDA, USA)
Jacob George (MHRA, GBR)

Patient viewpoint
Magdalena Daccord (FH Europe Foundation, CHE)

The CVCT Multi-Stakeholder Think Tank Moderated Debate

STRATEGIES TO ACHIEVE POWERFUL AND LONGER DURATION CHOLESTEROL LOWERING
Chairpersons: Pamela Morris (Mount Pleasant, SC, USA) & Greg Schwartz (Denver, CO, USA)

Panelists: Alex DePaoli (Rona Therapeutics, CHN), Puja Banka (Merck, USA), Eileen Craig (FDA, USA), Magdalena Daccord (FH Europe Foundation, CHE), Jason Duran (CRISPR Therapeutics, USA), Jacob George (MHRA, GBR), Jennifer Hellawell (Arrowhead pharmaceuticals, USA), Per Johannsen (AstraZeneca, SWE), Sekar Kathiresan (Verve Therapeutics, USA), Anastasia Lesogor (Novartis, CHE), Michelle O'Donoghue (Boston, MA, USA), Pamela Morris (Mount Pleasant, SC, USA), Neha Pagidipati (Durham, NC, USA), Greg Schwartz (Denver, CO, USA), Evan Stein (Lib Therapeutix, USA), Jie Zeng (Rona Therapeutics, CHN)

Palm court
Monday, December 7, 2026
11:00 -13:00

LP (a) TRIALS. HORIZON AND BEYOND THE HORIZON
Chairpersons: Leslie Cho (Cleveland, OH, USA) & Robert Rosenson (New York, NY, USA)

HORIZON – Main findings
Leslie Cho (Cleveland, OH, USA)

Epidemiologic and genetic/Mendelian randomization evidence: how well did it predict HORIZON, and what does that mean for OCEAN(a)-Outcomes, ACCLAIM-Lp(a), and MOVE-Lp(a)?
Borge Nordestgaard (Copenhagen, DNK)

Safety with different approaches to RNA inhibition, consequences on adherence and power size calculation in Lp(a) trials
Robert S. Rosenson (New York, NY, USA)

How HORIZON will frame the Lp(a) developments

Expanded use of pelacarsen beyond the very high-risk patient
Michelle O'Donoghue (Boston, MA, USA)

Role of biomarkers: why did Lp(a) reduction not predict benefit? What should the next biomarker strategy be, including OxPL and proteomics?
Sascha N. Goonewardena (Ann Arbor, MI, USA)

Which should be the preferred approach for patients with ASCVD and elevated Lp(a)? Targeted Lp(a) suppression or PCSK9 inhibition, or both?
Greg Schwartz (Denver, CO, USA)

Industry viewpoints
Hui Cao (Novartis, USA), Amit Khera (Verve Therapeutics, USA), Sam Tsimikas (Ionis, USA).

Regulatory viewpoint
Jacob George (MHRA, GBR)

Patient viewpoints
ShantaQuilette Carter (Pink Peppermint Project, USA)
Magdalena Daccord (FH Europe Foundation, CHE)
Hyvelle Ferguson-Davis (Heart Sistas, USA)

The CVCT Multi-Stakeholder Think Tank Moderated Debate

ADOPTION OF HORIZON RESULTS AND ADAPTION OF LP (a) TRIALS.
Chairpersons : Leslie Cho (Cleveland, OH, USA) & Robert Rosenson (New York, NY, USA)

Panelists: Hui Cao (Novartis, USA), ShantaQuilette Carter (Pink Peppermint Project, USA), Leslie Cho (Cleveland, OH, USA), Magdalena Daccord (FH Europe Foundation, CHE), Hyvelle Ferguson-Davis (Heart Sistas, USA), Charu Gandotra (FDA, USA) , Jacob George (MHRA, GBR), Sascha N. Goonewardena (Ann Arbor, MI, USA), Amit Khera (Verve Therapeutics, USA), Børge G. Nordestgaard (Copenhagen, DNK), Michelle O'Donoghue (Boston, MA, USA), Robert Rosenson (New York, NY, USA), Greg Schwartz (Denver, CO, USA), Tabassome Simon (Paris, FRA), Sam Tsimikas (Ionis, USA)

Palm court
Wednesday, December 9, 2026
14:00 -16:00

ESC European Society of Cardiology

ESC-CVCT JOINT SESSION
LBCT 2
Amyloid and Hypertrophic Cardiomyopathy
Chairpersons: Anjali Owens (Philadelphia, PA, USA) & Scott Solomon (Boston, MA, USA)

Session 1 (presentation times 8 min)

Nexiguran ziclumeran in ATTR amyloidosis with cardiomyopathy: safety and efficacy update with a propensity score–based comparison to a cohort from the National Amyloidosis Center
Gillmore1,*, SD Solomon2, B Claggett2, A Sheikh1, J Kachadourian3, D Smith3, J Olbertz3, M Levine3, DE Gutstein4, L Walsh3, M Fontana1,*
1National Amyloidosis Centre, University College London - London (United Kingdom), 2Brigham and Women's Hospital - Boston (United States), 3Intellia Therapeutics - Cambridge (United States), 4Regeneron Pharmaceuticals, Inc. - Tarrytown (United States)

Artificial Intelligence Enabled Multidomain Echocardiography For Monitoring Disease Progression In Transthyretin Cardiac Amyloidosis
A Sheikh1,*, P Gentile2, B Brinda1, J Jevgeni3, R Eiros Bachiller4, M Garcia De Pedro4, L Venneri5, S Kakhi5, A Martinez-Naharro5, G Almeida3, K Menacho6, B Meredith6, J Mansell5, S Solomon7, D Francis3, M Shun-Shin3, P Hawkins5, J Moon6, J Gillmore5, C Manisty6, M Fontana5
1National Amyloidosis Centre - London (United Kingdom), 2De Gasperis Cardio Center and Transplant Center, Niguarda Hospital Milan Italy - Milan (Italy), 3National Heart and Lung Institute, Imperial College London, Imperial College Healthcare NHS Trust, London, UK - London (United Kingdom), 4University of Salamanca - Salamanca (Spain), 5National Amyloid Centre - London (United Kingdom), 6Barts Heart Centre - London (United Kingdom), 7Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts - Boston (United States)

From Amyloid Deposition to Myocardial Response: Understanding the Biology of Cardiac Amyloidosis
A Sheikh1,*, P Gentile2, S Kakhi1, J Mansell1, B Thillainathan1, Y Razvi1, A Ioannou1, J Carruthers1, S Vasudevan1, s Hatipoglu1, L Venneri1, A Martinez-Naharro1, A Wechalekar1, C Whelan1, S Solomon3, P Hawkins1, J Gillmore1, M Fontana1
1National Amyloidosis Centre - London (United Kingdom), 2De Gasperis Cardio Center and Transplant Center, Niguarda Hospital Milan Italy - Milan (Italy), 3Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts - Boston (United States)

HLA-C*05:01 is significantly associated with transaminase elevations following dosing with nexiguran ziclumeran: an opportunity for precision medicine
MS Maurer1,*, SD Solomon2, M Fontana3, P Watkins4, D Lebwohl5,*, MD Pickard5, B Han5, J Olbertz5, N Rana5, T Karasarides5, J Kachadourian5, J Leonard5, J Overton6, G Abecasis6, A Baras6, C Kyratsous6, JD Gillmore3
1Columbia University Irving Medical Center - New York (United States), 2Brigham and Women's Hospital - Boston (United States), 3National Amyloidosis Centre, University College London - London (United Kingdom), 4Eshelman School of Pharmacy, University of North Carolina - Chapel Hill (United States), 5Intellia Therapeutics - Cambridge (United States), 6Regeneron Pharmaceuticals, Inc. - Tarrytown (United States)

Aficamten improves myocardial energetics, perfusion and oxygenation in symptomatic obstructive hypertrophic cardiomyopathy within 12 weeks
J Bell1,*, M Lacharie1, Z Ashkir1, N Clarke1, B Wang1, V Losev1, Z Ali1, L Valkovic1, P Gatehouse1, E Tunnicliffe1, A Masri2, M Maron3, S Saberi4, D Jacoby5, R Sohn5, J Godown5, S Heitner5, S Kupfer5, F Malik5, S Neubauer1, B Raman1,*
1Division of Cardiovascular Medicine, Radcliffe Department of Medicine, University of Oxford - Oxford (United Kingdom), 2Oregon Health and Science University - Portland, OR (United States), 3Lahey Hospital and Medical Center - Burlington, MA (United States), 4University of Michigan - Ann Arbor, MI (United States), 5Cytokinetics - San Francisco, CA (United States)

Discussant (10 min)
Ahmad Masri (Portland, OR, USA)

Q&A (10min)

Palm court
Wednesday, December 9, 2026
14:00 -16:00

ESC European Society of Cardiology

ESC-CVCT JOINT SESSION
LBCT 2
Amyloid and Hypertrophic Cardiomyopathy
Chairpersons: Anjali Owens (Philadelphia, PA, USA) & Scott Solomon (Boston, MA, USA)

Session 2 (presentation times 8 min)

Investigator-Guided Flexible Dose Escalation Strategy for the Treatment of Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy with Aficamten: An Analysis from the ACACIA-HCM and FOREST-HCM Trials
A Masri1,*, C Coats2, S Saberi3, C Ho4, D Massera5, P Elliott6, A Bhatia7, M Nassif8, J Godown9, S Heitner9, D Jacoby9, S Kupfer9, F Malik9, J Salazar-Mendiguchía9, R Sohn9, A Wohltman9, J Wei9, M Maron10
1Oregon Health and Science University - Portland (United States), 2University of Glasgow - Glasgow (United Kingdom), 3University of Michigan Health - Ann Arbor (United States), 4Brigham and Women's Hospital, Harvard Medical School - Boston (United States), 5Leon H. Charney Division of Cardiology, NYU Langone Health - New York (United States), 6Institute of Cardiovascular Science, Barts Heart Centre and University College London - London (United States), 7Lindner Research Center, The Christ Hospital - Cincinnati (United States), 8University of Missouri Kansas City Healthcare Institute for Innovations in Quality and Saint Luke's Mid America Heart Institute - Kansas City (United States), 9Cytokinetics, Incorporated - South San Francisco (United States), 10Lahey Hospital and Medical Center - Burlington (United States)

Aficamten Improves the Novel Boston Exercise Aggregate Physiologic Response Score in Hypertrophic Cardiomyopathy: A Prespecified Analysis of SEQUOIA-HCM, MAPLE-HCM and ACACIA-HCM
G Lewis1,*, S Williams1, B Clagget1, M Fifer1, P Garcia-Pavia2, I Kulac1, K Lim1, M Maron1, A Masri3, S Mcginnis1, F Moreno1, C Newlands4, I Iacopo5, P Divanji6, S Heitner6, D Jacoby6, S Kupfer6, F Malik6, J Salazar-Mendiguchía6, R Sohn6, A Wohltman6, S Zhuo6, C Coats7
1 - BOSTON (United States), 2 - Madrid (Spain), 3 - Portland (United States), 4 - Boston (United States), 5 - Florence (Italy), 6 - San Francisco (United States), 7 - Glasgow (United Kingdom)

Eplontersen and Outcomes in the CARDIO-TTRansform Trial: Prespecified Time-to-First Event and Win Statistics Analyses
A Masri1,*, H Yasuhiro2, BL Clagget2, K Ablasser3, AV Ambardekar4, F Cappelli5, SJ Carter6, SAM Cuddy2, MK Davis7, F Fernandes8, M Fontana9, P Garcia-Pavia10, JD Gillmore9, M Hanna11, MG Khouri12, JJ Mcdermott13, BW Sperry14, S Tsimikas15, E Platz13, FS Angeli13, MS Maurer16, SD Solomon2
1Oregon Health & Science University - Portland (United States), 2Brigham and Women's Hospital - Boston (United States), 3University of Graz - Graz (Austria), 4University of Colorado - Denver (United States), 5Careggi University Hospital - Florence (Italy), 6University of Utah - Salt Lake City (United States), 7The University of British Columbia - Vancouver (Canada), 8University of Sao Paulo - Sao Paolo (Brazil), 9University College London - London (United Kingdom), 10Hospital Universitario Puerta de Hierro - Madrid (Spain), 11Cleveland Clinic - Cleveland (United States), 12Duke University - Durham (United States), 13AstraZeneca - Gaithersburg (United States), 14UMKC - Kansas City (United States), 15Ionis - San Diego (United States), 16Columbia University - New York (United States)

Using a Large Language Model for Case Discovery in Transthyretin Cardiac Amyloidosis
A Cruz-Solbes1,*, S Zeng1, A Abovich1, S Cuddy1, S Dorbala1, B Claggett1, S Solomon1, J Cunningham1
1Mass General Brigham - Boston (United States)

Discussant (10 min)
Caroline Coats (Glasgow, UK)

Q&A (10min)

Palm court
Monday, December 7, 2026
16:30 -19:00

CARDIAC TARGETED BIOLOGICS, REGENERATION, REALITY, AND REINVENTION
Chairpersons : Philippe Menasche (Paris, FRA) & Emerson Perin (Houston, TX, USA)

Issues related to routes of administration
Mapping-guided catheter delivery of iPSC-derived cardiomyocyte spheroids
Keiichi Fukuda (Heartseed, JAP)

Catheter-based delivery of iPSC-derived cardiomyocytes
Eugene Wang (HELP Therapeutics, CHN)

Regulatory viewpoint
Chinwe Okoro (FDA, USA)

Gene therapy for boosting cardiomyocyte proliferation: the SALVADOR-HF trial
Emerson Perin (Houston, TX, USA)

siRNA for the treatment of heart failure
Thomas Thum (Hannover, GER)

Secretome-based therapy
Eduardo Marban (Los Angeles, CA, USA), Ambarish Pandey (Dallas, TX, USA), Vinny Jindal (Secretome Tx, USA)

In silico and digital twins for cell therapy development
Blanca Rodriguez (Oxford, GBR)

Developmental and regulatory enabling aspects of human cardiac organoid platform
Stanko Skrtic (HeartBeat.bio, AUT)

Autologous Mitochondrial Transplantation for No-Option Critical Limb Ischemia
Aijun Sun (Shanghai, CN)

Industry briefings (2-3 slides, 5 minutes)
Peter Altman (BioCardia, USA), Silviu Itescu (Mesoblast, AUS), Stanko Skrtic (HeartBeat.bio, AUT), Eugene Wang (HELP Therapeutics, CHN)

Patients viewpoints
Magdalena Daccord (FH Europe Foundation, CHE)

Closing remarks
Philippe Menasche (Paris, FRA)

The CVCT Multi-Stakeholder Think Tank Moderated Debate

SHOULD CARDIOLOGY ADOPT ACCELERATED PATHWAYS FOR REGENERATIVE THERAPIES?
Chairpersons : Philippe Menasche (Paris, FRA) & Emerson Perin (Houston, TX, USA)

Panelists: Peter Altman (BioCardia, USA), Magdalena Daccord (FH Europe Foundation, CHE), Keiichi Fukuda (Heartseed, JPN), Silviu Itescu (Mesoblast, AUS), Vinny Jindal (Secretome Tx, USA), Eduardo Marban (Los Angeles, CA, USA), Philippe Menasché (Paris, FRA), Chinwe Okoro (FDA, USA), Ambarish Pandey (Dallas, TX, USA), Emerson Perin (Houston, TX, USA), Blanca Rodriguez (Oxford, GBR), Stanko Skrtic (HeartBeat.bio, AUT), Aijun Sun (Shanghai, CN), Thomas Thum (Hannover, GER), Eugene Wang (HELP Therapeutics, CHN)

East
Monday, December 7, 2026
08:30 -10:30

CARDIAC AMYLOIDOSIS TRIALS CHANGING LANDSCAPE AND IMPLEMENTATION ISSUES
Chairpersons: Mariana Fontana (London, GBR) and Iacopo Olivotto (Florence, ITA)

Diagnosis of cardiac amyloidosis—the tip of an iceberg?
Mariana Fontana (London, GBR)

Should we systematically screen for ATTR?
Francesco Cappelli (Florence, Italy)

What should future control groups in future trials look like in an era of acoramidis/tafamidis + silencers?
Ahmad Masri (Portland, OR, USA)

Innovative trial design options.
Mariana Fontana (London, GBR)

What are the financial realities for ATTR management?
Dhruv Kazi (Boston, MA, USA)

What does holistic care look like for people with ATTR-CM?
Justin Grodin (Dallas, TX, USA)

Industry Viewpoints
Sameer Bansilal (Alnylam, USA), Robert Blaustein (Immutrin, USA), Gillian Murtagh (Bridgebio, USA), Manju Revanna (NovoNordisk, DNK), Liron Walsh (Intellia, USA),

Regulatory viewpoint: Approvability issues
Karim Mikhail (FDA, USA)

The CVCT Multi-Stakeholder Think Tank Moderated Debate

TAKING ATTR-CARDIOMYOPATHY TREATMENT TO THE NEXT LEVEL: IDENTIFYING PATIENTS, ASSESSING FRAILTY, INTEGRATING THERAPIES.
Chairpersons: Mariana Fontana (London, GBR) and Iacopo Olivotto (Florence, ITA)

Panelists: Alberto Aimo (Pisa, IT), Sameer Bansilal (Alnylam, USA), Robert Blaustein (Immutrin, USA), Francesco Cappelli (Florence, ITA), Mariana Fontana (London, GBR), Justin Grodin (Dallas, TX, USA), Dhruv Kazi(Boston, MA, USA), Mori Krantz (FDA, USA), Ahmad Masri (Portland, OR, USA), Karim Mikhail (FDA, USA), Gillian Murtagh (BridgeBio, Palo Alto, CA, USA), Iacopo Olivotto (Florence, ITA), Christina Quarta (Alexion, USA), Manju Revanna (NovoNordisk, DNK), Liron Walsh (Intellia, USA)

East
Monday, December 7, 2026
11:00 -13:00

THE END OF THE BEGINNING: WHAT NEXT FOR DRUG TRIALS IN HYPERTROPHIC CARDIOMYOPATHY?

Chairpersons: Perry Elliott (London, GBR) and Iacopo Olivotto (Florence, ITA)

Lessons from ODYSSEY and ACACIA -HCM.
Differences in molecule, design, execution, or chance in non-obstructive HCM?
Anjali Owens (Philadelphia, PA, USA)

Do we need 'next (third) generation' myosin modulators?
Martin Maron (Boston, MA, USA)

Metabolic modulators and mitotropes: We've been here before—so what is new this time?
Caroline Coats (Glasgow, GBR)

Is it possible to do hard end-point trials in hypertrophic cardiomyopathy?
Ahmad Masri (Portland, OR, USA)

The case of pediatric trials
Joseph Rossano (Philadelphia, PA, USA)

Industry perspectives
Michael Ayers (Edgewise, USA), Arnaud Bastien (BMS, USA), Gabriel Brooks (Solid Biosciences, USA), Marc Evanchik (BraveHeart Bio, USA), Justin Godown (Cytokinetics, USA), Natasha Paterson (Tenaya Therapeutics, USA)

Regulatory viewpoints
Fortunato Senatore (FDA, USA)
Ann Punnoose (FDA, USA)

Patient viewpoints
Lisa Salberg (HCMA, USA)
Francesca Musso (HCM Patient, ITA)

The CVCT Multi-Stakeholder Think Tank Moderated Debate

HYPERTROPHIC CARDIOMYOPATHY TRIALS. THE SURROGATE vs. HARD OUTCOME DILEMMA

Chairpersons: Perry Elliott (London, GBR) and Iacopo Olivotto (Florence, ITA)

Panelists: Michael Ayers (Edgewise, USA), Arnaud Bastien (BMS, USA), Gabriel Brooks (Solid Biosciences, USA), Caroline Coats (Glasgow, GBR), Marc Evanchik (BraveHeart Bio, USA), Berry Elliott (London, GBR), Justin Godown (Cytokinetics, USA), Martin Maron (Boston, MA, USA), Ahmad Masri (Portland, OR, USA), Francesca Musso (HCM Patient, ITA), Iacopo Olivotto (Florence, ITA), Anjali Owens (Philadelphia, PA, USA), Natasha Paterson (Tenaya Therapeutics, USA), Ann Punnoose (FDA, USA), Joseph Rossano (Philadelphia, PA, USA), Lisa Salberg (HCMA, Denville, NJ, USA), Fortunato Senatore (FDA, USA)

East
Monday, December 7, 2026
14:00 -16:00

HEART FAILURE COLLABORATORY

CVCT - HEART FAILURE Collaboratory joint session
PATIENT-REPORTED OUTCOMES – ESSENTIAL, BUT HOW?
Chairpersons: Mona Fiuzat (Washington, DC, USA) & Chris O'Connor (Washington, DC, USA)

History And Challenges with Current PRO Endpoints
Javed Butler (Dallas, TX, USA)

What Is an Anchor and Minimally Clinically Important Difference, and How To Assess It?
Folke Folkvaljon (AstraZeneca, ESP)

Population Mean Difference and Responder Analysis
Mitch Psotka (FDA, USA)

Does Distribution-Based Analysis Solve the Problem?
Cordula Zeller (Boehringer Ingelheim, GER)

Do We Need Pros? NYHA Class as Endpoint? How to use Anchor?
Charu Gandotra (FDA, USA)

PROs in Win Ratio and in Open-Label Trials
Eric Leifer (NIH/NHLBI, USA)

NIH Viewpoint
Eric Leifer (NIH, USA)

Regulatory Viewpoint
Charu Gandotra (FDA, USA)
Lisa Plummer (FDA, USA)

Industry Viewpoints
Phillip Adamson (CVRx, USA), Lothar Roessig (AskBio, GER)

Patient viewpoints
Rhonda Monroe (Charlotte, NC, USA)
Steven Macari (AVEC, FRA)

The CVCT Multi-Stakeholder Think Tank Moderated Debate

REFINING PATIENT-REPORTED OUTCOMES USE IN CLINICAL TRIALS.
Chairpersons: Mona Fiuzat (Washington, DC, USA) & Chris O'Connor (Washington, DC, USA)

Panelists: Phillip Adamson (CVRx, USA), Martina Brueckmann (Roche, CH), Javed Butler (Dallas, TX, USA), Mona Fiuzat (Washington, DC, USA), Folke Folkvaljon (AstraZeneca, ESP), Charu Gandotra (FDA, USA), Eric Leifer (NIH, USA), Steven Macari (AVEC, FRA), Rhonda Monroe (Charlotte, NC, USA), Christopher O'Connor (Washington, DC, USA), Joanna Osmanska (Glasgow, UK), Lisa Plummer (FDA, USA), Mitch Psotka (FDA, USA), Lothar Roessig (AskBio, GER), Frances Varian (Sheffield, GBR), Cordula Zeller (Boehringer Ingelheim, GER), Bram Zuckerman (FDA, USA)

East
Monday, December 7, 2026
16:30 -19:30

HYPERTENSION TRIALS
PART I
NOVEL TARGETED THERAPEUTICS —NAVIGATING THE OPPORTUNITIES AND OBSTACLES
Chairpersons: Jenifer Brown (Boston, MA, USA) & Neha Pagidipati (Durham, NC, USA)

Are all forms of difficult-to-control or resistant hypertension caused by aldosterone dysregulation?
Jenifer Brown (Boston, MA, USA)

Acute Severe Hypertension: Disease? Target? Bystandar?
Jay Edelberg (Kardigan, USA)

Aldosterone Synthase Inhibitors (ASIs): Will they transform hypertension management?
Bryan Williams (London, GBR)

Small Interfering RNA (siRNA) Against Angiotensinogen: Going Beyond Conventional RAS Blockade for Hypertension Treatment and CVD Prevention?
Neha Pagidipati (Durham, NC, USA)

Have Endothelin Receptor Antagonists Finally Found Their Place in Resistant Hypertension?
Markus Schlaich (Perth, AUS)

Industry Viewpoints
Martine Clozel (Idorsia, CHE), Shira Perl (AstraZeneca, USA)

Regulatory viewpoints
William Herzog (FDA, USA)

Panel Discussion & Q&A

HAVE WE REACHED PEAK INNOVATION IN HYPERTENSION THERAPIES?
Chairpersons: Jenifer Brown (Boston, MA, USA) & Neha Pagidipati (Durham, NC, USA)

Panelists: Michel Azizi (Paris, FRA), Jenifer Brown (Boston, MA, USA), Shon Chakrabarti (Recor Medical, USA), Martine Clozel (Idorsia, CHE), Naomi Fisher (Boston, MA, USA), Lee Fleisher (Rubrum Advising, USA), William Herzog (FDA, USA), Amer Joseph (Idorsia, CHE), Neha Pagidipati (Durham, NC, USA), Shira Perl (AstraZeneca, USA), Garrett Pilcher (Medtronic, USA), Anthony Rodgers (Sydney, AUS), Markus Schlaich (Perth, AUS), Roland Schmieder (Erlangen, GER), Lawrence Tallon (MHRA, GBR), Bryan Williams (London, GBR), Dion Zappe (Alnylam, USA)

East
Monday, December 7, 2026
16:00 -19:00

HYPERTENSION TRIALS
PART II
ARE STANDARD RCT DESIGNS KILLING POTENTIALLY EFFECTIVE ANTI-HYPERTENSIVE DRUGS AND DEVICE-BASED THERAPY?
Chairpersons: Michel Azizi (Paris, FRA) & Bryan Williams (London, GBR)

Learning from Recent Failures of Novel Drug and Device Development for Hypertension. How would I design my next trial?

Drug Therapy
Michel Azizi (Paris, FRA)

Device-based therapy
Roland Schmieder (Erlangen, GER)

Navigating Regulatory Guidelines: Where Does RDN Stand in 2026 in an Era of Novel Approaches To Treatment?
Naomi Fisher (Boston, MA, USA)

Ubiquitous Single-Pill multidrug combination therapy for hypertension: Multiple drugs or better-targeted therapy?
Anthony Rodgers (Sydney, AUS)

Signal or Noise? Why Hypertension Trials Must Inform Clinical Decision-Making, Not Just Pharmacology
Nelson Wang (Melbourne, AUS)

Industry Viewpoints
Shon Chakrabarti (Recor Medical, USA), Amer Joseph (Idorsia, CHE), Dion Zappe (Alnylam, USA),

Payers' viewpoint
Lee Fleisher (Rubrum Advising, USA)

The CVCT Multi-Stakeholder Think Tank Debate

BRIDGING THE GAP BETWEEN INNOVATION AND IMPLEMENTATION: CAN CHEAP, GENERIC POLYPILLS FOR THE MASSES COEXIST WITH INNOVATIVE TARGETED THERAPIES?
Chairpersons: Michel Azizi (Paris, FRA) & Bryan Williams (London, GBR)

Panelists: Michel Azizi (Paris, FRA), Jenifer Brown (Boston, MA, USA), Shon Chakrabarti (Recor Medical, USA), Martine Clozel (Idorsia, CHE), Naomi Fisher (Boston, MA, USA), Lee Fleisher (Rubrum Advising, USA), William Herzog (FDA, USA), Amer Joseph (Idorsia, CHE), Neha Pagidipati (Durham, NC, USA), Shira Perl (AstraZeneca, USA), Garrett Pilcher (Medtronic, USA), Anthony Rodgers (Sydney, AUS), Markus Schlaich (Perth, AUS), Roland Schmieder (Erlangen, GER), Nelson Wang (Melbourne, AUS), Bryan Williams (London, GBR), Dion Zappe (Alnylam, USA)

State
Monday, December 7, 2026
08:30 -10:30

ALDOSTERONE IN CARDIOVASCULAR-KIDNEY-METABOLISM DISEASES
ENDURING AND EMERGING SCIENCE, NEW OPPORTUNITIES AND CLINICAL TRIALS LANDSCAPE
Chairpersons: Bertram Pitt (Ann Arbor, MI, USA) & Faiez Zannad (Paris, FRA)

Prevalence and Clinical Impact of Hyperaldosteronism and Hypercortisolism in CKM disease
Michel Azizi (Paris, FRA)

How far can we suppress maladaptive mineralocorticoid biology without toxicity? How translational science may inform clinical trials.
Morag Young (Melbourne, AUS)

Is aldosterone level the wrong target, and MR overactivation the real disease biology?
Bertram Pitt (Ann Arbor, MI, USA)

ASI trials update
Javed Butler (Dallas, TX, USA)

nsMRA trials update
Scott Solomon (Boston, MA, USA)

Primary care physician viewpoint. Why are we failing to detect hyperaldosteronism in routine CKM care?"
Javier Morales (New York, NY, USA)

Industry viewpoints
Maria Borentain (Bayer, GER), Mikhail Kosiborod (AstraZeneca, USA),

What level of incremental benefit justifies premium pricing?
Dora Hughes (CMS, USA)
Lee Fleisher (Rubrum Advising, USA)

The CVCT Multi-Stakeholder Think Tank Debate

ALDOSTERONE IN CARDIOVASCULAR-KIDNEY-METABOLISM DISEASES
ENDURING AND EMERGING SCIENCE, NEW OPPORTUNITIES AND CLINICAL TRIALS LANDSCAPE
Chairpersons: Bertram Pitt (Ann Arbor, MI, USA) & Faiez Zannad (Paris, FRA)

Panelists: Michel Azizi (Paris, FRA), Maria Borentain (Bayer, GER), Javed Butler (Dallas, TX, USA), Lee Fleisher (Rubrum Advising, USA), Dora Hughes (CMS, USA), Masatake Kobayashi (Tokyo, JPN), Mikhail Kosiborod (AstraZeneca, USA), Javier Morales (New York, NY, USA), Bertram Pitt (Ann Arbor, MI, USA), Scott Solomon (Boston, MA, USA), Morag Young (Melbourne, AUS)

State
Monday, December 7, 2026
11:00 -13:00

CARDIO-KIDNEY-METABOLIC TRIALS. HOW TO COPE WITH MULTIPLE DRUGS, MULTI-ORGAN COMPOSITE ENDPOINTS AND MULTIPLE SOURCES OF EVIDENCE.

Chairpersons: Hiddo L Heerspink (Groningen, NED) & Clare Arnott (Sydney, AU)

Targeting combined multiorgan cardiovascular and kidney benefits. Rationale and opportunities
Nephrologist viewpoint
Hiddo L Heerspink (Groningen, NED)

Cardiologist viewpoint
Faiez Zannad (Paris, FRA)

Primary Care Physician viewpoint
TBD

How to select the right patient population in multiorgan cardio-kidney-metabolic clinical trials?
Brendon Neuen (Sydney, AUS)

Hitting multiple birds with a single stone
Virtues and limitations of composite endpoints. Statistician viewpoints.
Jan Tijssen (Brussels, BEL)

Can dual indications be claimed with a single trial? Regulatory viewpoint.
Aliza Thompson (FDA, USA)

How may payers value single drug multi-organ benefits?
Dora Hughes (CMS, USA), Lee Fleisher (Rubrum Advising, USA)

Trials investigating multidrug CKM stack. Add-on, vs. head-to-head, vs. non-inferiority trial designs.

Clinical viewpoint
Will Herrington (Oxford, GBR)

Statistical viewpoint
Brian Claggett (Boston, MA, USA)

Regulatory viewpoints
Aliza Thompson (FDA, USA), Alar Irs (EMA, EST)

Industry viewpoints.
Meike Brinker (Bayer, GER), Martina Brueckmann (Roche, CH), Jersey Chen (Lilly, USA), raziella Collu (AstraZeneca, USA), Dustin Little (Nuvectis Pharma, Inc, USA), Peter Erland Marstrand (NovoNordisk, DNK)

Patient viewpoints
Steven Macari (AVEC, FRA)

The CVCT Multi-Stakeholder Think Tank Moderated Debate

CARDIO-KIDNEY-METABOLIC TRIALS. HOW TO COPE WITH MULTIPLE DRUGS, MULTI-ORGAN COMPOSITE ENDPOINTS AND MULTIPLE SOURCES OF EVIDENCE

Chairpersons: Hiddo Heerspink (Groningen, NED) & Clare Arnott (Sydney, AU)

Panelists: Clare Arnott (Sydney, AU), Martina Brueckmann (Roche, CH), Meike Brinker (Bayer, GER), Jersey Chen (Lilly, USA), Brian Claggett (Boston, MA, USA), Graziella Collu (AstraZeneca, USA, Hiddo L. Heerspink (Groningen, NED), Lee Fleisher (Rubrum Advising, USA), Will Herrington (Oxford, GBR, Dora Hughes (CMS, USA), Alar Irs (EMA, EST), Dustin Little (Nuvectis Pharma, Inc, USA), Steven Macari (AVEC, FRA), Peter Erland Marstrand (NovoNordisk, DNK), Brendon Neuen (Sydney, AUS), Norman Stockbridge (S&S Consulting, USA), Aliza Thompson (FDA, USA), Jan Tijssen (Brussels, BEL) Faiez Zannad (Paris, FRA)

State
Monday, December 7, 2026
14:00 -16:00

CVCT-NIH-WOMEN AS ONE-CIRCULATION JOURNAL JOINT SESSION
BEYOND REPRESENTATION: DESIGNING CARDIOVASCULAR TRIALS AROUND WOMEN'S BIOLOGY AND LIFE COURSE
Chairpersons: Robert Califf (Durham, NC, USA) & Martha Gulati (Los Angeles, CA, USA)

Cardiovascular disease (CVD) in women evolves across the lifespan, shaped by reproductive biology, hormonal transitions, and social and environmental influences. A life-course framework highlights pregnancy and menopause as two critical points where cardiovascular risk is either revealed or accelerated. These windows provide important opportunities for early detection, targeted prevention, and improved clinical trial design. However, significant gaps persist, including the underrepresentation of pregnant and perimenopausal women in trials, limited randomized evidence, and a lack of longitudinal studies that track risk across decades.
Reframing lifespan transitions as strategic opportunities for detection and intervention can enable a proactive, lifespan-based approach to prevention and improve cardiovascular outcomes.

Current and future unmet needs in women's cardiovascular health research
Martha Gulati (Los Angeles, CA, USA)

Global priorities and funding opportunities for advancing women's cardiovascular research
Janine Clayton (NIH/ OWH, USA)

Peripartum and Postpartum interventions to improve short- and long-term maternal and fetal cardiovascular health
Garima Arora (Birmingham, AL, USA)

Trials' opportunities in menopause as a vascular transition.
Chrisandra L. Shufelt (Jacksonville, FL, USA)

Ischemia with no obstructive coronary artery disease: A female-enriched phenotypes in HFpEF trials?
Odayme Quesada (Cincinnati, OH, USA)

Obesity–metabolic trials in women
Neha Pagidipati (Durham, NC, USA)

Regulatory expectations for sex-specific evidence
Kaveeta Vasisht (FDA, USA)

Industry viewpoints
Amy Ford (Lilly, USA), Sofia Gerward (Novo Nordisk, USA), Luba Soskin (Bayer, CHE),

Patient Viewpoints
Celina Gorre (WomenHeart, USA)

The CVCT Multi-Stakeholder Think Tank Moderated Debate

SETTING PRIORITIES FOR RESEARCH, POLICY, AND PRACTICE IN WOMEN'S HEALTH
Chairpersons: Robert Califf (Durham, NC, USA) & Martha Gulati (Los Angeles, CA, USA)

Panelists: Garima Arora (Birmingham, AL, USA), Juan Camilo Arjona Ferreira (Organon, COL), Robert Califf (Durham, NC, USA), Ediina Cenko (Bologna, IT), Janine Clayton (NIH/ OWH, USA), Amy Ford (Lilly, USA), Sofia Gerward (Novo Nordisk, USA), Celina Gorre (WomenHeart, USA), Martha Gulati (Los Angeles, CA, USA), Neha Pagidipati (Durham, NC, USA), Odayme Quesada (Cincinnati, OH, USA), Luba Soskin (Bayer, CHE), Chrisandra L. Shufelt (Jacksonville, FL, USA), Kaveeta Vasisht (FDA, USA)

State
Monday, December 7, 2026
16:30 -19:30

STRATEGIES FOR CLINICAL TRIAL DESIGN IN - PATIENTS AT RISK OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASE

Part 1

HOW BEST TO DEFINE TARGET POPULATIONS?

Chairpersons: Marc Sabatine (Boston, MA, USA) & Lale Tokgozoglu (Ankara, TUR)

Comparison of guideline recommendations: Sorting out the “at-risk” trial population
Lale Tokgozoglu (Ankara, TUR)

Guiding the next generation of trials in high-risk event-free patients
Erin Bohula (Boston, MA, USA)

Can blood pressure and LDL cholesterol be targeted at once with a single bullet?
Sergio Fazio (Corsera, USA)

Target patient population: Screening of atherosclerosis risk

3-dimensional ultrasonography of carotid and iliofemoral arteries
Valentin Fuster (New York, NY, USA)

CT angiography plaque volume and plaque characteristics
Nick Nurmohamed (Amsterdam, NED)

Genetic instruments
Ron Do (New York, NY, USA)

Proteomic profiling
Sascha Goonewardena (Ann Arbor, MI, USA)

The CVCT Multi-Stakeholder Think Tank Moderated Debate

HOW BEST TO DEFINE TARGET POPULATIONS?

Chairpersons: Marc Sabatine (Boston, MA, USA) & Lale Tokgozoglu (Ankara, TUR)

Panelists: Erin Bohula (Boston, MA, USA), Brian Claggett (Boston, MA, USA),), Ron Do (New York, NY, USA), Sergio Fazio (Corsera, USA), Valentin Fuster (New York, NY, USA), Charu Gandotra (FDA, USA), Sascha Goonewardena (Ann Arbor, MI, USA), Adrian Hernandez (Durham, NC, USA), Paulus Kirchhof (Hamburg, GER),), Darren McGuire (Dallas, TX, USA), Guiomar Mendieta-Badimon (Barcelona, ESP), Nick Nurmohamed (Amsterdam, NED), Heng Tony Qian (Olink, USA), Marc Sabatine (Boston, MA, USA), Patrick Schlömer (BAYER, GER), Nishant Shah (Durham, NC, USA), John Sharretts (ex FDA, USA), Lale Tokgozoglu (Ankara, TUR), Raymond Soccio (FDA, USA), Aliza Thompson (FDA, USA), Muthiah Vaduganathan (Boston, MA, USA), Stephen Wiviott (AstraZeneca, USA)

State
Monday, December 7, 2026
16:00 -19:00

Part 2
CVCT-DCRI JOINT SESSION
ENDPOINT FOR PREVENTION BEYOND ASCVD
Chairpersons: Adrian Hernandez (Durham, NC, USA) & Guiomar Mendieta-Badimon (Barcelona, ESP)

Heart failure: Hospitalization or outpatient diagnosis?
Muthiah Vaduganathan (Boston, MA, USA)

Atrial fibrillation: Clinically relevant burden?
Paulus Kirchhof (Hamburg, GER)

Diabetes: The prevention vs. masking conundrum and does it matter?
Darren McGuire (Dallas, TX, USA)

Guiding the next generation of trials in high-risk event-free patients
Nishant Shah (Durham, NC, USA)

Statistical viewpoint
Brian Claggett (Boston, MA, USA)

Industry viewpoint
Stephen Wiviott (AstraZeneca, USA), Patrick Schlömer (BAYER, GER), Heng Tony Qian (Olink, USA)

NIH-NHLBI viewpoint.
Yves Rosenberg (NIH, USA)

Regulatory viewpoint
Charu Gandotra (FDA, USA)

The CVCT Multi-Stakeholder Think Tank Moderated Debate

PREVENTION TRIALS IN AT RISK POPULATIONS – HOW TO ACCELERATE INNOVATION?
Chairpersons: Adrian Hernandez (Durham, NC, USA) & Guiomar Mendieta-Badimon (Barcelona, ESP)

Panelists: Erin Bohula (Boston, MA, USA), Brian Claggett (Boston, MA, USA), Ron Do (New York, NY, USA), Sergio Fazio (Corsera, USA), Valentin Fuster (New York, NY, USA), Charu Gandotra (FDA, USA), Sascha Goonewardena (Ann Arbor, MI, USA), Adrian Hernandez (Durham, NC, USA), Paulus Kirchhof (Hamburg, GER), Darren McGuire (Dallas, TX, USA), Guiomar Mendieta-Badimon (Barcelona, ESP), Heng Tony Qian (Olink, USA), Yves Rosenberg (NIH, USA), Marc Sabatine (Boston, MA, USA), Patrick Schlömer (BAYER, GER), Nishant Shah (Durham, NC, USA), John Sharretts (ex FDA, USA), Lale Tokgozoglu (Ankara, TUR), Raymond Soccio (FDA, USA), Aliza Thompson (FDA, USA), Muthiah Vaduganathan (Boston, MA, USA), Stephen Wiviott (AstraZeneca, USA)

Chinese
Wednesday, December 9, 2026
11:00 -13:00

ESC-CVCT JOINT SESSION
LBCT 1
Heart Failure. Cell and Gene Therapy
Chairpersons: Kieran Docherty (Glasgow, UK) & Silvia Priori (Pavia, ITA)

Session a: Heart Failure (presentation times 8 min)

Baseline Left Ventricular Ejection Fraction and Response to Cardiac Microcurrent Therapy: An Exploratory Pooled Analysis
M Fudim1,*, F Kallel2, D Kosevic3, J Nunez4, G Van Hout5, T Biering-Sørensen6, W Mullens7, N Hamid8, J Cavalcante8, T Friede9, S Zieroth10, J Butler11, J Singh12, S Anker13,*
1Duke University - Durham (United States), 2Berlin Heals - Berlin (Germany), 3Didinje Cardiovascular Institute - Belgrade (Serbia), 4Valencia Clínico de Valencia - Valencia (Spain), 5St. Antonius Ziekenhuis - Nieuwegein (The Netherlands), 6Gentofte University Hospital - Copenhagen (Denmark), 7Hospital Oost-Limburg - Genk (Belgium), 8Allina Health Minneapolis Heart Institute - Minneapolis (United States), 9University Medical Center Göttingen - Göttingen (Germany), 10University of Manitoba - Winnipeg (Canada), 11Baylor Scott & White Health - Dallas (United States), 12Massachusetts General Hospital - Boston (United States), 13Charite University Hospital - Berlin (Germany)

A non-invasive hemodynamic-guided strategy to prevent heart failure decompensation: 12-month outcomes of a single-arm trial
A Böhm1,*, J Lucká2, A Segev3, J Janková1, V Hlodáková1, M Kollárová1, N Jajcay1, M Spilák4, F Skorec5, J Ševková2, Š Karolčík1, P Dragunová1, K Hasáková1, M Selvek6, R Mužik6, P Cambell7, A Butkovský8, J Danková9, K Kováčová10, L Horaniová11, M Mydliar12, V Soková13, Z Danišková14, S Balogh15, M Fabini16, A Henry17, A Cannata18, G Savarese19, F Koehler20, C Tschöpe21, B Bezák22
1Premedix - Bratislava (Slovakia), 2National Institute of Cardiovascular Diseases - Bratislava (Slovakia), 3Centre for Cardiovascular Innovation, Division of Cardiology, University of British Columbia - Vancouver (Canada), 4Faculty of Medicine, Comenius University in Bratislava - Bratislava (Slovakia), 5Department of Radiology, AGEL Radiology s.r.o., - Bratislava (Slovakia), 6Dôvera Health Insurance Company - Bratislava (Slovakia), 7Department of Cardiology, Southern Trust, Craigavon Area Hospital - Portadown (United Kingdom), 8Internal and Cardiology Outpatient Clinic - Trebišov (Slovakia), 9Department of Internal Medicine and Cardiology Outpatient Clinic, NsP Nové Mesto nad Váhom - Nové Mesto nad Váhom (Slovakia), 10Kardiológia KK s.r.o - Bratislava (Slovakia), 11Kardionitra s.r.o - Nitra (Slovakia), 12Intermedical, Interná ambulancia - Bratislava (Slovakia), 13KardioHC s.r.o. - Hlohovec (Czechia), 14Nemocnica Alexandra Wintera, n.o. - Piešťany (Slovakia), 15BalMedic s.r.o. - Sala (Slovakia), 16Nemocnica Poprad a.s. - Poprad (Slovakia), 17John Radcliffe Hospital, Oxford University Hospitals NHS Foundation Trust - Oxford (United Kingdom), 18King's College London - London (United Kingdom), 19Department of Clinical Science and Education at Södersjukhuset, Karolinska Institutet - Stockholm (Sweden), 20German Centre for Cardiovascular Research, Charité Universitätsmedizin Berlin - Berlin (Germany), 21Department of Cardiology, Angiology and Intensive Care Medicine (CVK), Charité—Universitätsmedizin Berlin - Berlin (Germany), 22Faculty of Medicine, University of Ostrava - Ostrava (Czechia)

Impact Of Intravenous Iron Repletion on Mechanisms of Exercise Intolerance in Heart Failure with Preserved Ejection Fraction: The IRONMET-HFpEF Trial Responder Analysis
G Lewis1,*, N Horick2, S Williams1, F Moreno1, D Cocca-Spofford1, T Ikoma1, P Gupta1, C Camphausen1, K Lim1, L Caccamo1, C Soydara1, S Mcginnis1, C Newlands1, A Minasian1, N Iskenderian1, I Landsteiner1, J Joseph1, B Iyer1, H Tattersfield1, E Moore1, V Platt1, S Lee1, R Malhotra1
1Mass General Brigham Heart and Vascular Institute, Cardiology Division - BOSTON (United States), 2Massachusetts General Hospital Department of Biostatistics - BOSTON (United States)

Quantile time ratios to assess clinical benefits of heart failure therapies measured by delays in cardiovascular outcomes: experience from DAPA-HF and DELIVER trials
SB Gasparyan1,*, J Kupferman1, BL Claggett2, A Henderson3, JJV Mcmurray3, SD Solomon2, R Myte4
1AstraZeneca - Boston (United States), 2Brigham and Women's Hospital - Boston (United States), 3University of Glasgow - Glasgow (United Kingdom), 4AstraZeneca - Gothenburg (Sweden)

Registry-to-randomization: A multicenter heart failure registry as epidemiological infrastructure for an HFrEF polypill trial in Sri Lanka
S Ajanthan1,*, S Mahawattage1, G Galappatthy2, P Lakshman3, A Wanniarachchi4, S Rajapakse5, S Premaratne6, M Rahuman7, G Mayurathan8, A Agarwal9, A De Silva10
1RemediumOne - Colombo (Sri Lanka), 2National Hospital of Sri Lanka - Colombo (Sri Lanka), 3Jaffna Teaching Hospital - Jaffna (Sri Lanka), 4Negombo district General Hospital - Negombo (Sri Lanka), 5Colombo North Teaching Hospital - Ragama (Sri Lanka), 6National Hospital Galle - Galle (Sri Lanka), 7Colombo South Teaching Hospital - Kalubowila (Sri Lanka), 8National Hospital Kandy - Kandy (Sri Lanka), 9Washington University in St. Louis - St. Louis (United States), 10University of Kelaniya - Ragama (Sri Lanka)

Contemporary Transition in Epidemiology, Phenotypes and Cause-Specific Mortality of Over 800,000 Incident Heart Failure Cases in the US from 2000 to 2025
P Selvaganesan1, I Helmy2, M Karnib2, JGF Cleland3, YNV Reddy4, R Zakeri5, J Fanning6, JC Fang7, AR Vest8, MN Osman9, R Amuthan2, J Sahadevan2, A Pandey10, J Mcmurray3, M Packer11, V Sundaram9,*
1Case Western Reserve University - Cleveland (United States), 2Louis Stokes Cleveland VA Medical Center, Case Western Reserve University - Cleveland (United States), 3University of Glasgow - Glasgow (United Kingdom), 4Mayo Clinic - Rochester (United States), 5King's College London - London (United Kingdom), 6University of Queensland - Brisbane (Australia), 7University of Utah - Salt Lake City (United States), 8Cleveland Clinic Foundation - Cleveland (United States), 9Louis Stokes Cleveland VA Medical Center, University Hospitals Harrington Heart & Vascular Institute, Case Western Reserve University - Cleveland (United States), 10UT Southwestern Medical Center - Dallas (United States), 11Baylor Heart and Vascular Institute, Baylor University Medical Center - Dallas (United States)

Discussant (10 min): John Teerlink (San Francisco, CA, USA)
Q&A (10min)

Chinese
Wednesday, December 9, 2026
11:00 -13:00

ESC-CVCT JOINT SESSION
LBCT 1
Heart Failure. Cell and Gene Therapy
Chairpersons: Kieran Docherty (Glasgow, UK) & Silvia Priori (Pavia, ITA)

Session b: Cell and Gene Therapy (presentation times 8 min)

LAPiS Trial: 52-Week Results from a Phase 1/2 Clinical Trial of iPSC-Derived Cardiomyocyte Replacement Therapy Combined with CABG in HFrEF Patients
Y Ichihara1,*, H Hattori2, N Kikuchi2, S Haruki2, K Morita1, M Hattori1, T Kaneko3, K Fukuda3, S Nunoda4, J Yamaguchi2, H Niinami1
1Tokyo Women's Medical University, Department of Cardiovascular Surgery - Tokyo (Japan), 2Tokyo Women's Medical University, Department of Cardiology - Tokyo (Japan), 3Heartseed Inc. - Tokyo (Japan), 4Tokyo Women's Medical University Graduate School of Medicine, Department of Therapeutic Strategy for Severe Heart Failure - Tokyo (Japan)

Functional Recovery After LVAD Implantation With Adjunctive hiPSC-Derived Cardiomyocyte Therapy: Interim Results From an Exploratory Study
E Wang1, Y Shao2,*, J Du2,*
1HELP Therapeutics - Nanjing (China), 2Department of Cardiovascular Surgery, Jiangsu Provincial People's Hospital (The First Affiliated Hospital of Nanjing Medical University) - Nanjing (China)

Three-year follow-up of the first-in-human trial of umiposgene parvec (AB-1002) in non-ischemic heart failure
T Henry1,*, E Chung1, D Murray2, J Traverse3, L Roberts4, L Ervin5, J Potts5, R Shafi5, L Roessig5, C Jiang5, S Sanganalmath5, R Hajjar6
1The Carl and Edyth Linder Center for Research and Education at The Christ Hospital - Cincinnati (United States), 2University of Wisconsin School of Medicine and Public Health - Madison (United States), 3Minneapolis Heart Institute - Minneapolis (United States), 4AskBio UK LTD - Edinburgh (United Kingdom), 5AskBio Inc., Research Triangle Park - Durham (United States), 6Gene and Cell Therapy Institute, Massachusetts General Brigham - Cambridge (United States)

First-in-Man Treatment of Dilated Cardiomyopathy by Repeated Intravenous Infusions of the Secretome of Cardiovascular Progenitor Cells
P Menasché1,*, N Renault2, JR Fabreguettes1, N Aissaoui1, T Puscas1, P Baudinaud1, A Bacher1, B Sabatier1, E Pinet1, D Giraud1, C Granier3, N Benhamouda1, A Gey1, H Pereira1, D Loews4, F Dingli4, H Blons1, V Bellamy5, JL Taupin1, E Tartour1, J Larghero1, A Hagège1
1AP-HP - Paris (France), 2FCDI - Madison (United States), 3CH Orléans - Orléans (France), 4Institut Curie - Paris (France), 5Inserm - Paris (France)

Transepicardial Intramyocardial HiCM-188 Injection During CABG for Advanced Ischemic Heart Failure: Results From HEAL-AHF
E Wang1,*, R Jing1,*
1HELP Therapeutics - Nanjing (China)

Discussant (10 min)
Svati Shah (Durham, NC, USA)

Q&A (10min)

Chinese
Monday, December 7, 2026
16:30 -18:30

CVCT/PATIENT ADVOCACY CONSORTIUM JOINT SESSION
MAKING CLINICAL TRIAL EVIDENCE UNDERSTANDABLE TO PATIENTS —AND TO EVERYONE OUTSIDE THE TRIALIST COMMUNITY?
PLAIN-LANGUAGE TRIAL SUMMARIES PUBLICATIONS.
Chairpersons : Marc Bains (HeartLife, CAN) & Faiez Zannad (Paris, FRA)

CVCT is to announce the important CVCT PLSP new initiative
With the participation of patient trialists and journal editors

Plain language summaries for patients sit at the intersection of three otherwise separate problems:widespread, often underestimated gaps in health literacy; a clinical encounter structurally too brief to transmit complex medical information; and the well-documented link between patient understanding and treatment adherence. None of these problems is fully solvable by better bedside manner alone. A well-constructed PLSP — tested for readability, free of unexplained jargon, and ideally reviewed by actual patients before publication — gives people durable, revisitable access to the information a rushed visit cannot fully deliver. As regulators, journals, funders, and pharmaceutical sponsors increasingly require these summaries as a condition of publication, the opportunity is not just to check a compliance box, but to meaningfully close the gap between what medical research knows and what the patients living with that research actually understand.

«Plain language» to change clinical actions and trial implementation in the real world.

The EU perspective
Mark Petrie (Glasgow, GBR)

The US perspective
Shahzeb Khan (Dallas, TX, USA)

No jargon, please. Just tell me what this trial means. What do non-trialists actually want to know?
Rhonda Monroe (Charlotte, NC, USA)

Readable is not necessarily understandable: what health-literacy research teaches us
TBD

What errors would make a PLS unacceptable—even if patients and non-trialists find it easy to read?
John Mandrola (Louisville, KY, USA)

The Human-AI loop. Responsible use of artificial intelligence in creating plain language summaries
Karen Gainey (Sydney, AUS)

The roles of citable plain-language summary journal publications.
TBD

Patient editor viewpoint: Patient review for PLSP
Marc Bains (HeartLife, GBR),

The CVCT PLSP Initiative: From Trial Results to Non-Trialist Understanding
What minimum standard should CVCT adopt today?
Javed Butler (Dalla, TX, USA)

The CVCT Multi-Stakeholder Think Tank Moderated Debate

Making clinical trial evidence understandable for everyone.
Why and how should scientific publication no longer be the final stop?
Chairpersons : Marc Bains (HeartLife, CAN) & Faiez Zannad (Paris, FRA)

Panelists : Marc Bains (HeartLife, GBR), Javed Butler (Dallas, TX, USA), Karen Gainey (Sydney, AUS), Shahzeb Khan (Dallas, TX, USA), Steven Macari (AVEC, FRA), John Mandrola (Louisville, KY, USA), Rhonda Monroe (Charlotte, NC, USA), Mark Petrie (Glasgow, GBR), Faiez Zannad (Paris, FRA)

Ballroom
Monday, December 7, 2026
08:30 -10:30

AI MASTER CLASS 1
AI IN CARDIOVASCULAR DEVICES AND HARDWARE
HOW SHOULD EVIDENCE STANDARDS FOR AI-ENABLED DEVICES ALIGN WITH TRADITIONAL DEVICE EVALUATION?
Chairpersons: Kirsten Bibbins-Domingo (JAMA, USA) & Harriette Van Spall (Hamilton, CAN)

AI in Devices and Hardware. What Evidence Do We Need? Defining future evaluation frameworks
Rick Abramson (FDA, USA)
08:40–08:50
Planning an AI in Devices trial: regulatory pathways (510(k), De Novo, PMA) and what each demands
Christine Kupchik (Colorado, CO, USA)

Regulatory viewpoint:
Stephen Browning (FDA, USA)

From bench to bedside: evaluating a locked algorithm across multiple clinical contexts
Udo Hoffmann (Cleerly / MGH, USA)

Prospective validation, real-world evidence, and pragmatic trial designs for device-AI
Milos Vukadinovic (Los Angeles, CA, USA)

Case study: AI-Echocardiography, Core lab automation and solving measurement variability
Sheldon Litwin (Charleston, SC, USA)
Lovedeep Dhingra (New Haven, CT, USA)

Wearables, arrhythmia algorithms, and post-market performance monitoring after clearance
Mintu Turakhia (Stanford, CA, USA)

Generalizability, dataset shift, and the demographic gap in device-AI validation
Nick Gossen (Dandelion, USA)

Industry viewpoints
David Albert (AliveCor, USA), Campbell Rogers (Heartflow, USA), Bakul Patel (Google, USA)

Regulatory guidance for planning an AI in Devices trial.
Lawrence Tallon (MHRA, UK)

Investor perspective: how capital is allocated and what signals matter for device-AI
David Rosenthal (Alleycorp, USA)

The CVCT Multi-Stakeholder Think Tank Moderated Debate

AI IN CARDIOVASCULAR DEVICES AND HARDWARE: HOW SHOULD EVIDENCE STANDARDS FOR AI-ENABLED DEVICES ALIGN WITH TRADITIONAL DEVICE EVALUATION?
Chairpersons : Kirsten Bibbins-Domingo (JAMA, USA) & Harriette Van Spall (Hamilton, CAN)

Panelists: Rick Abramson (FDA, USA), David Albert (AliveCor, USA), Kirsten Bibbins-Domingo (JAMA, USA), Lovedeep Dhingra (New Haven, CT, USA), Nick Gossen (Dandelion, USA), Udo Hoffmann (Cleerly/MGH, USA), Christine Kupchik (Colorado, CO, USA), Sheldon Litwin (Charleston, SC, USA), Bakul Patel (Google, USA), Campbell Rogers (HeartFlow, USA), David Rosenthal (Alleycorp , USA), Lawrence Tallon (MHRA, UK), Mintu Turakhia (Stanford, CA, USA), Harriette Van Spall (Hamilton, CAN), Milos Vukadinovic (Los Angeles, CA, USA)

Ballroom
Monday, December 7, 2026
11:00 -13:00

AI MASTER CLASS 2
CLINICAL DECISION SOFTWARE: EVALUATING ADAPTIVE ALGORITHMS AND SaMD FOR CARDIOVASCULAR RISK PREDICTION, IMAGING DIAGNOSTICS, TRIAGE, AND DECISION SUPPORT: PREDETERMINED CHANGE CONTROL PLANS, CLINICAL UTILITY VS. ACCURACY, AND THE SaMD FRAMEWORK

Chairpersons : Carolyn Lam (Singapore, SGP) & Harlan Krumholz (JACC, USA)

Required standards for evolving systems: Unbiased Evaluation of Generative AI and Autonomous Software as a Medical Device and Clinical Decision Support software
Issa Dahabreh (Boston, MA, USA)

From risk prediction to clinical action: when does AI improve cardiovascular prevention?
John Deanfield (London, GBR)

Why high AUC does not equal clinical value: decision-consequential endpoints
Ann Marie Navar (Dallas, TX, USA)

Predetermined Change Control Plans: enabling software updates without full re-review
Rob Kazmierski (MCRA, USA)

Alert fatigue, workflow disruption, clinician trust: the implementation science of CDS
Aline Pedroso (San Francisco,CA, USA)

Can you run a traditional RCT on software that updates quarterly? Adaptive trial designs for SaMD
Harriette Van Spall (Hamilton, CAN)

The CDS exemption boundary: where does decision support end and regulated SaMD begin?
Aneesh Deoras (FDA, USA)

What is the appropriate regulatory strategy for generative AI in medicine?
Evangelos K Oikonomou (New Haven, CT, USA)

Industry viewpoints
Benjamin Rosand (Cleo Health, USA)

Regulatory viewpoints
Jordan Pomeroy (FDA, USA)

Investor perspective: how capital is allocated and what signals matter for SaMD
David Rosenthal (Alleycorp, USA)

The CVCT Multi-Stakeholder Think Tank Moderated Debate

ADAPTIVE CLINICAL DECISION SOFTWARE: WHAT LEVEL AND TYPE OF EVIDENCE SHOULD BE REQUIRED FOR CLINICIANS TO TRUST AND ADOPT AI DIAGNOSTIC AND DECISION SUPPORT TOOLS?

Moderators: Carolyn Lam (Singapore, SGP) & Harlan Krumholz (JACC, USA)

Panelists: Stephen Browning (FDA, USA), Issa Dahabreh (Boston, MA, USA), John Deanfield (London, GBR), Aneesh Deoras (FDA, USA), Harlan Krumholz (JACC, USA), Carolyn Lam (Singapore, SGP), Ann Marie Navar (Dallas, TX, USA), Aline Pedroso (San Francisco,CA, USA), Jordan Pomeroy (FDA, USA), Rob Kazmierski (MCRA, USA), Evangelos K Oikonomou (New Haven, CT, USA), Bakul Patel (Google, USA), Benjamin Rosand (Cleo Health, USA), David Rosenthal (Alleycorp, USA), John Spertus (Kansas City, MO, USA), Harriette Van Spall (Hamilton, CAN)

Ballroom
Monday, December 7, 2026
14:00 -16:00

iCVCT # 5
STRATEGIZING ENTERING THE CLINICAL STAGE FOR HF MEDTECH STARTUPS
Chairpersons: Dan Burkhoff (New York, NY, USA) & Martin Leon (New York, NY, USA)

Overview. The innovation landscape of HF devices
Innovators' viewpoint
Howard Levin (Coridea, USA)

Investors' viewpoints
Hanson Gifford (The Foundry, USA)

Regulatory viewpoint
Andrew Farb (FDA, USA)

Recent learnings from pilot studies

Devices to treat Heart Failure
Dan Burkhoff (New York, NY, USA)

Devices to treat Structural Heart Disease
Martin Leon (New York, NY, USA)

The competitive landscape. What is in the pipeline? Industry presentations

Do we still need to test every device the same way? The role of virtual patients and in-silico trials
Simon Sonntag (Virtonomy, GER)

Industry viewpoint. Shifting from Feasibility to Pivotal Global Trials (Structural & Interatrial Shunts)
William Abraham (V-Wave, ISR), Jeff Closs (Ancora, USA), John Laschinger (Edwards, USA), Howard Levin (Coridea, USA), Kate Stohlman (Corvia, USA).

The evolving HTA regulatory landscape
Joint Clinical Assessment under the EU HTA Regulation
Marco Marchetti (AGENAS, IT)

The evolving HTA regulatory landscape
Lawrence Tallon (MHRA, GBR)

Joint Clinical Assessment under the EU HTA Regulation
Marco Marchetti (AGENAS, IT)

The CVCT Multi-Stakeholder Think Tank Moderated Debate

STRATEGIZING ENTERING THE CLINICAL STAGE FOR HF MEDTECH STARTUPS
Chairpersons: Dan Burkhoff (New York, NY, USA) & Martin Leon (New York, NY, USA)

Panelists: William Abraham (V-Wave, ISR), Dan Burkhoff (New York, NY, USA), Jeff Closs (Ancora, USA), Andrew Farb (FDA, USA), Hanson Gifford (The Foundry, USA), Howard Levin (Coridea, USA), Martin Leon (New York, NY, USA), John Laschinger (Edwards, USA), Marco Marchetti (AGENAS, IT), Kate Stohlman (Corvia, USA), Lawrence Tallon (MHRA, GBR)

Ballroom
Monday, December 7, 2026
16:30 -19:30

STRATEGIZING ENTERING THE CLINICAL STAGE FOR BIOTECH STARTUPS.
Part 1: HEART FAILURE
Chairpersons: Peter Libby (Boston, MA, USA) & Milton Packer (Dallas, TX, USA)

Innovators viewpoint
Lars Lund (Stockholm, SWE)

The innovation landscape:

US Regulatory viewpoint
Robert Califf (Durham, NC, USA)

EU Regulatory viewpoint
Jacob George (MHRA, GBR)

The innovation landscape and what de-risking do investors expect?
Craig Gordon (GordonMD Global Investment LP, USA)

Recent conceptual advances and Heart failure phase 2 trials
Milton Packer (Dallas, TX, USA)

The competitive landscape. What is in the heart failure pipeline? Industry presentations

Activin signaling inhibitors
Alessia Urbinati (Merck, USA)

Endotrophin antagonists
Federica Genovese (Nordic Bioscience, DNK)
Laurent Audoly (PriveBio, USA)

FGF21 Receptor Agonists
Christine Garrett (Preload Therapeutics, USA)

PDE9 inhibitors
Howard Surks (Cardurion, USA)

Targeting Titin N2B
Richard Nkulikiyinka (GenKardia, USA)

The CVCT Multi-Stakeholder Think Tank Moderated Debate

Part 1: Heart Failure
Chairpersons: Peter Libby (Boston, MA, USA) & Milton Packer (Dallas, TX, USA)

Panelists: Hafid Ait-Oufella (Polygon, FRA), Laurent Audoly (PriveBio, USA), David Bauman (Schrödinger, USA), Brieana Buckley (Editas Medicine, USA), Robert Califf (Durham, NC, USA), Chris Farina (Abcentra, USA), Christine Garrett (Preload Therapeutics, USA), Federica Genovese (Nordic Bioscience, DNK), Jacob George (MHRA, GBR), Craig Gordon (GordonMD Global Investment LP, USA), Filip Janku (Monterosa, USA), Peter Libby (Boston, MA, USA), Lars Lund (Stockholm, SWE), Richard Nkulikiyinka (GenKardia, USA), Milton Packer (Dallas, TX, USA), Mahesh Patel (Merck, USA), Howard Surks (Cardurion, USA), Alessia Urbinati (Merck, USA)

Ballroom
Monday, December 7, 2026
16:00 -19:00

STRATEGIZING ENTERING THE CLINICAL STAGE FOR BIOTECH STARTUPS.
Part 2: INFLAMMATION ATHEROSCLEROSIS
Chairpersons: Peter Libby (Boston, MA, USA) & Milton Packer (Dallas, TX, USA)

Recent conceptual advances and phase 2 inflammation Atherosclerosis Trials
Peter Libby (Boston, MA, USA)

The competitive landscape. What is in the inflammation pipeline? Industry presentations

What is new in computational drug design
David Bauman (Schrodinger, USA)

Targeted Protein Degradation in Therapeutics
Filip Janku (Monterosa, USA)

Immunological Targets in Cardiac Disease
Hafid Ait Oufella (Polygon, FRA)

Plaque-targeted Anti-Inflammatory Therapy: Targeting Oxidized LDL
Chris Farina (Abcentra, USA)

Repairing Broken Genes with CRISPR
Brieana Buckley (Editas,Medicine, USA)

Oral NLRP3 inflammasome inhibition
Jyothis George (Rezera, GBR)

The CVCT Multi-Stakeholder Think Tank Moderated Debate

Part 2: Inflammation and Atherosclerosis
Chairpersons: Peter Libby (Boston, MA, USA) & Milton Packer (Dallas, TX, USA)

Panelists: Hafid Ait-Oufella (Polygon, FRA), Laurent Audoly (PriveBio, USA), David Bauman (Schrödinger, USA), Brieana Buckley (Editas Medicine, USA), Robert Califf (Durham, NC, USA), Chris Farina (Abcentra, USA), Christine Garrett (Preload Therapeutics, USA), Federica Genovese (Nordic Bioscience, DNK), Jacob George (MHRA, GBR), Craig Gordon (GordonMD Global Investment LP, USA), Filip Janku (Monterosa, USA), Peter Libby (Boston, MA, USA), Lars Lund (Stockholm, SWE), Richard Nkulikiyinka (GenKardia, USA), Milton Packer (Dallas, TX, USA), Mahesh Patel (Merck, USA),Howard Surks (Cardurion, USA), Alessia Urbinati (Merck, USA)

Palm court
Tuesday, December 8, 2026
08:30 -10:30

iCVCT #1
THROMBOSIS TRIALS. CAN WE UNCOUPLE THROMBOSIS FROM BLEEDING?
Chairpersons: Michael Gibson (Boston, MA, USA) & Carolyn Lam (Singapore, SGP)

From neutral OCEANIC AF to positive OCEANIC-Stroke trial. Clot mechanics, active drug comparator, and levels of target inhibition.
Mike Sharma (Hamilton, ON, CAN)

FXI inhibition AF trials.

Understanding Cerebral Hemorrhage Risk and its Relevance to Stroke Prevention Treatment Choices
Edip Gurol (Boston, MA, USA)

What comparator(s) and what endpoints in FXI VAD trials?"
Mandeep Mehra (Boston, MA, USA)

Mechanistic insights from the ROXI-CATH tests REGN9933 and REGN7508 contact activation (pic lines and indwelling catheters) trials
Jeff Weitz (Hamilton, CAN)

Are current trial well designed to figure whether FXIa inhibition is a new anticoagulant class — or a precision antithrombotic for selected thrombo-inflammatory vascular beds
Ken Mahaffey (Stanford, CA, USA)

Speed versus diagnostic certainty — Add-on versus replacement strategies?
Michael Gibson (Boston, MA, USA)

Industry viewpoints
Anders Gabrielsen (Ribocure, SWE), David Gutstein (Regeneron, USA), András Gruber (Aronora, USA) Eva Muehlhofer (Bayer, GER)

The CVCT Multi-Stakeholder Think Tank Moderated Debate

THE FUTURE OF THROMBOSIS INNOVATION. LARGE TARGETS VS. PRECISION-BIOLOGY BIOTECH ECOSYSTEMS?"
Chairpersons: Michael Gibson (Boston, MA, USA) & Carolyn Lam (Singapore, SGP)

Panelists: Anders Gabrielsen (Ribocure, SWE), Michael Gibson (Boston, MA, USA), András Gruber (Aronora, USA), Edip Gurol (Boston, MA, USA), David Gutstein (Regeneron, USA), Carolyn Lam (Singapore, SGP), Ken Mahaffey (Stanford, CA, USA), Mandeep Mehra (Boston, MA, USA), Eva Muehlhofer (Bayer, GER), Mike Sharma (Hamilton, ON, CAN), Jeffrey Weitz (Hamilton, CAN)

Palm court
Tuesday, December 8, 2026
11:00 -13:00

INDUSTRY-ACADEMIA TRIALISTS' INTERACTIONS
Chairpersons: Biykem Bozkurt (Houston, TX, USA) & Scott Solomon (Boston, MA, USA)

Innovation and Excellence - The Importance of Industry-Academic Collaborations
Rob Califf (Durham, NC, USA)

Safeguarding the Industry-Academic Relationship
Marc Pfeffer (Boston, MA, USA)

Investigator Access to Data
Scott Solomon (Boston, MA, USA)

Use of biosamples and the Investigators' Access to biobanks
Faiez Zannad (Paris, FRA)

Journal Editors' Viewpoints
Flavia Geraldes (The Lancet, GBR)
Harlan Krumholz (JACC, USA)
Jane Leopold (NEJM, USA)
Bradley Maron (Circulation, USA)

Ensuring Trust in Clinical Trials – Patient Perspective
Corinne Hudson (Pumping Marvellous, GBR)

Industry Viewpoints
Sameer Bansilal (Alnylam, USA), Antonieta Bomfim (Boehringer Ingelheim, GER), Steve Heitner (Cytokinetics, USA), Mahesh Patel (Merck, USA), Katja Rohwedder (Bayer, GER)

The CVCT Multi-Stakeholder Think Tank Moderated Debate

INDUSTRY-ACADEMIA TRIALISTS' INTERACTIONS: SHARING IS TRUST!
Chairpersons: Biykem Bozkurt (Houston, TX, USA) & Scott D. Solomon (Boston, MA, USA)

Panelists: Sameer Bansilal (Alnylam, USA), (Bayer, GER) , Antonieta Bomfim (Boehringer Ingelheim, GER), Biykem Bozkurt (Houston, TX, USA), Robert Califf (Durham, NC, USA), Mariana Fontana (London, GBR) Flavia Geraldes (The Lancet, GBR), Steve Heitner (Cytokinetics, USA), Corinne Hudson (Pumping Marvellous, GBR), Harlan Krumholz (JACC, USA), Jane Leopold (NEJM, USA), Bradley Maron (Circulation, USA), Mahesh Patel (Merck, USA), Marc Pfeffer (Boston, MA, USA), Katja Rohwedder (Bayer, GER), Scott D. Solomon (Boston, MA, USA), Faiez Zannad (Paris, FRA)

Palm court
Tuesday, December 8, 2026
14:30 -16:30

OBESITY MEDICINE: NEW DATA AND BIG QUESTIONS
Chairpersons: Ildi Lingvay (Dallas, TX, USA) & Naveed Sattar (Glasgow, GBR)

Known and recent cardiovascular outcome data from incretin-based CVOTs
Ildi Lingvay (Dallas, TX, USA)

Women's health, liver disease and cardiovascular prevention
Marat Fudim (Durham, NC, USA)

Ongoing CVOTs of obesity medicines: what gaps in knowledge will they fill?
Jennifer Green (Durham, NC, USA)

To what extent is weight loss the mechanism of CV and other benefits: what do we really know?
Naveed Sattar (Glasgow, GBR)

How to investigate the anti-inflammatory effects of GLP-1 agonists in clinical trials?
Jorge Plutzky (Boston, MA, USA)

Do incremental MOAs for weight loss really make a difference?
Javed Butler (Dallas, TX, USA)

The Death of the Pure Placebo? Navigating GLP-1 Cross-Over in Future Outcome Trials
Odd Erik (Roche, CH)

Industry viewpoint: What future CVOTs design would companies like FDA to consider
Filip Knop (NovoNordisk, DNK),

What future CVOTs design would regulator be willing to accept?
Raymond Soccio (FDA, USA)

Patient viewpoint: What do patients wish to see in future trials?
Joseph Nadglowski (Obesity Action Coalition, USA)

The CVCT Multi-Stakeholder Think Tank Moderated Debate

NEXT FRONTIERS FOR OBESITY TRIALS
Chairpersons: Ildi Lingvay (Dallas, TX, USA) & Naveed Sattar (Glasgow, GBR)

Panelists: Javed Butler (Dallas, TX, USA), Odd Erik (Roche, CH), Marat Fudim (Durham, NC, USA) Jennifer Green (Durham, NC, USA), Filip Knop (NovoNordisk, DNK), Ildiko Lingvay (Dallas, TX, USA), Joseph Nadglowski (Obesity Action Coalition, USA), Steven Nissen (Cleveland, OH, USA), Jorge Plutzky (Boston, MA, USA), Naveed Sattar (Glasgow, GBR), Raymond Soccio (FDA, USA), Faiez Zannad (Paris, FRA)

Tuesday, December 8, 2026
13:30 - 14:20

Keynote Lecture
Victor J. Dzau (Boston, MA, USA)
“A Crossroads in Cardiovascular Medicine: Scientific Progress and Barriers to Impact”
Q&A

Marc Pfeffer (Boston, MA, USA)
“No time to smell the roses”
Q&A

Palm court
Tuesday, December 8, 2026
17:00 -19:00

OBESITY MEDICINES: BODY COMPOSITION, ASSESSMENTS, TARGETS AND CONCERNS
Chairpersons: Pam Taub (San Diego, CA, USA) & Subodh Verma (Toronto, CAN)

Body composition changes in health and disease, and association with outcomes
Jason Gill (Glasgow, GBR)

Body composition changes with obesity medicines and surgery
Jennifer Linge (Linköping, SWE)

Beyond weight loss: Muscle and bone preservation with GLP-1 RAs, and will they translate into better functionality?
Jason Gill (Glasgow, GBR)

What target should we treat to: a certain weight, resolution of comorbidities, or both
Ildiko Lingvay (Dallas, TX, USA)

Weight loss concerns: potential for too much weight loss in some and rapid regain post cessation / weight cycling?
Naveed Sattar (Glasgow, GBR)

Should future trials investigate the causes and consequences of discontinuation of weight loss therapy.
Antonio Ceriello (Milan,ITA)

NHLBI viewpoint
Laurie Donze (NIH/NHLBI, USA)

Primary care physician viewpoint: What should tell my obese patients about their muscles?
TBD

Industry viewpoints
Yousuf Ali (Boehringer Ingelheim, GER)
TBD

Regulatory Perspective : Reflections on muscle- building agents PLUS need for trials with weight loss targets
Raymond Soccio (FDA, USA)
TBD

Patient viewpoint
Joseph Nadglowski (Obesity Action Coalition, USA)

The CVCT Multi-Stakeholder Think Tank Moderated Debate

HOW TO DESIGN OBESITY MEDICINES TRIALS BEYOND WEIGHT LOSS
Chairpersons: Pam Taub (San Diego, CA, USA) & Subodh Verma (Toronto, CAN)

Panelists: Yousuf Ali (Boehringer Ingelheim, GER), Antonio Ceriello (Milan,ITA), Laurie Donze (NIH, USA), Jason Gill (Glasgow, GBR), Jennifer Linge (Linköping, SWE), Ildiko Lingvay (Dallas, TX, USA), Steven Macari (AVEC, FRA), Joseph Nadglowski (Obesity Action Coalition, USA), Naveed Sattar (Glasgow, GBR), Raymond Soccio (FDA, USA), Pam Taub (San Diego, CA, USA), Subodh Verma (Toronto, CAN)

East
Tuesday, December 8, 2026
08:30 -10:30

ZEUS TRIAL DEEP DIVE : UNDERSTANDING AND INTERPRETING THE RESULTS OF ZEUS
Chairpersons: Paul Ridker (Boston, MA, USA) & Jean Claude Tardif (Montreal, CAN)

ZEUS rationale and primary results
Paul Ridker (Boston, MA, USA)

The consequence of ZEUS on the ongoing inflammation trials
Jean-Claude Tardif (Montreal, CAN)

What populations are most appropriate targets in cardio-immunology trials:

Is CKD an appropriate target population.
Hiddo Heerspink (Groningen, NLD)

Post-MI inflammation-enriched patients
Adrian Hernandez (Durham, NC, USA)

Heart failure: ATHENA and HERMES
Guiomar Mendieta Badimon (Madrid, ESP)

Therapeutic window and safety issues in cardiovascular inflammation trials
Jean Claude Tardif (Montreal, Canada)

Industry viewpoint
Andres Hvelplund (NovoNordisk, DEN)

Regulatory viewpoints
Aliza Thompson (FDA, USA)

Clinical development learnings from ZEUS
Mads Engelmann (Copenhague, DEN)

Patient viewpoint
Patrick Gee (iAdvocate, USA)

The CVCT Multi-Stakeholder Think Tank Moderated Debate

ZEUS TRIAL DEEP DIVE: IMPLICATIONS FOR CKM TRIALS
Chairpersons: Paul Ridker (Boston, MA, USA) & Jean Claude Tardif (Montreal, CAN)

Panelists: Mads Engelmann (Copenhagen, DEN), Patrick Gee (iAdvocate, USA), Hiddo Heerspink (Groningen, NED), Adrian Hernandez (Durham, NC, USA), Andres Hvelplund (NovoNordisk, DEN), Guiomar Mendieta Badimon (Madrid, ESP), Paul Ridker (Boston, MA, USA), Jean Claude Tardif (Montreal, CAN), Aliza Thompson (FDA, USA)

East
Tuesday, December 8, 2026
11:00 -13:00

ANTI-INFLAMMATORY TREATMENT OF ASCVD: BEYOND ZEUS, WHAT IS NEXT?
Chairpersons: Wolfgang Koenig (Munich, GER) & Giovanna Liuzzo (Rome, IT)

Reverse translation: What have we learned from completed trials?
Peter Libby (Boston, MA, USA)

Targeted immune modulation for atherosclerosis
Klaus Ley (Augusta, GA, USA)

Can proteomics/multiomics provide novel insights into the best targets?
Manuel Mayr (London, GBR)

Could trials investigating an anti-inflammatory transcriptome in T-cells mediated by EPA finally solve the controversy?
Preston Mason (Boston, MA, USA)

T reg cell-based therapies—how can we identify the immunotolerant patients with the best benefit/risk ratio
Rouchelle Sriranjan-Rothwell (Cambridge, GBR)

IL-1β, direct NLRP3 inhibitors – Offsetting risk versus benefit.
Paul Ridker (Boston, MA, USA)

Industry Viewpoints
Chris O`Donnell (Novartis, CH), Kristen Fortney (BioAge, USA), Jyothis George (Rezera, GBR), Maria Sejersten Ripa (Novo Nordisk, DNK), Marzia Rigolli (Eli Lilly, USA)

Regulatory Viewpoint
Mori Krantz (FDA, USA)

The CVCT Multi-Stakeholder Think Tank Moderated Debate

ANTI-INFLAMMATORY TREATMENT OF ASCVD: WHAT HAVE WE LEARNED FROM RECENT TRIALS? HOW TO TEST NEW TARGETS IN TRIALS?
Chairpersons: Wolfgang Koenig (Munich, GER) & Giovanna Liuzzo (Rome, ITA)

Panelists: Chris O`Donnell (Novartis, CH), Kristen Fortney (BioAge, USA), Jyothis George (Rezera, GBR), Mori Krantz (FDA, USA), Wolfgang Koenig (Munich, GER) ; Klaus Ley (Augusta, GA, USA), Peter Libby (Boston, MA, USA), Giovanna Liuzzo (Rome, ITA), Preston Mason (Boston, MA, USA), Manuel Mayr (London, GBR), Jorge Plutzky (Boston, MA, USA), Paul Ridker (Boston, MA, USA), Marzia Rigolli (Eli Lilly, USA), Maria Sejersten Ripa (Novo Nordisk, DNK), Fortunato Senatore (FDA, USA), Rouchelle Sriranjan-Rothwell (Cambridge, GBR)

East
Tuesday, December 8, 2026
14:30 -16:30

PULMONARY ARTERIAL HYPERTENSION
PULMONARY ARTERIAL HYPERTENSION INNOVATIVE TRIALS DESIGNS
Chairpersons: Marc Humbert (Paris, FRA) & Vallerie McLaughlin (Ann Arbor, MI, USA)

PDGF as a target in PAH: lessons from IMPRESS, IMPAHCT and PROSERA
Olivier Sitbon (Paris, FRA)

PDGF as a target in PAH: design of IMPROVE-PAH
Kelly Chin (Dallas, TX, USA)

Sotatercept in PAH: central, hematologic, and peripheral mechanisms of benefit
Yogesh Reddy (Rochester, MN, USA)

Activin signaling inhibitors safety signals in PAH trials
Iona Preston (Boston, MA, USA)

Drug development on top of drugs targeting four pathways: how?
Anna Hemnes (Nashville, TN, USA)

Investigator Viewpoints
Nick Hill (Boston, MA, USA)
Anjali Vaidya (Philadelphia, PA, USA)

Patient Viewpoint
Coleen Brunetti (Pulmonary Hypertension Association, USA)

Industry Viewpoints
Chris Cabell (Inhibikase, USA), Mahesh Patel (Merck, USA), Franck Rahaghi (United Therapeutics, USA), Rainer Zimmermann (Gossamer, USA)

The CVCT Multi-Stakeholder Think Tank Moderated Debate

PULMONARY ARTERIAL HYPERTENSION INNOVATIVE DESIGNS
Chairpersons: Marc Humbert (Paris, FRA) & Vallerie McLaughlin (Ann Arbor, MI)

Panelists: Coleen Brunetti (Pulmonary Hypertension Association), Kelly Chin (Dallas, TX, USA), Chris Cabel (Inhibikase, USA), Bjorn Dahlof (Cereno, SWE), Hap Farber (Boston, MA, USA), Mardi Gomberg-Maitland (Washington, DC, USA), Anna Hemnes (Nashville, TN), Nick Hill (Boston, MA, USA), Marc Humbert (Paris, FRA), Steve Kawut (Philadelphia, PA, USA), Bradley Maron (Circulation, USA), Vallerie McLaughlin (Ann Arbor, MI, USA), Mahesh Patel (Merck, USA), Iona Preston (Boston, MA, USA), Mitch Psotka (FDA, USA), Franck Rahaghi (United Therapeutics, USA), Yogesh Reddy (Rochester, MN, USA), Carlos Sanmarco (Pulmovant, USA), Oksana Shlobin (Falls Church, VA, USA), Olivier Sitbon (Paris, FRA), Derek Solum (United Therapeutics, NC), Mark Toshner (Cambridge, GBR), Anjali Vaidya (Philadelphia, PA, USA), Jean-Luc Vachiéry (Brussels, BE), Corey Ventetuolo (Providence, RI), Jason Weatherald (Edmonton, CA), Rainer Zimmermann (Gossamer, USA)

East
Tuesday, December 8, 2026
17:00 -19:00

CVCT GREAT DEBATES
Chairpersons: Jane Leopold (NEJM, USA) & Milton Packer (Dallas, TX, USA)

Debate 1

Oral diuretic intensification should be included in the composite endpoint for HF failure
Pro: Harriette Van Spall (Hamilton, CAN)
Con: Javed Butler (Dallas, TX, USA)

Discussion

Debate 2

It is time to have multi-organ multi-endpoint composites for cardiovascular trials
Pro: Faiez Zannad (Paris, FRA)
Con: Milton Packer (Dallas, TX, USA)

Discussion

Debate 3

Device trials should be judged differently than drug trials due to size/design limitations
Pro: William Abraham (Columbus, OH, USA)
Con: Mark Petrie (Glasgow, GBR)

Discussion

Debate 4

Coronary revascularization should be included in the expanded MACE endpoints
Pro: Roxana Mehran (New York, NY, USA)
Con: Scott Solomon (Boston, MA, USA)

Discussion

The CVCT Multi-Stakeholder Think Tank Moderated Debate

CVCT GREAT DEBATES
Chairpersons: Jane Leopold (NEJM, USA) & Milton Packer (Dallas, TX, USA)

Panelists: William Abraham (Columbus, OH, USA), Javed Butler (Dallas, TX, USA), Maria Rosa Costanzo (Naperville, IL, USA), Jane Leopold (NEJM, USA), Roxana Mehran (New York, NY, USA), Milton Packer (Dallas, TX, USA), Mark Petrie (Glasgow, GBR), Scott D. Solomon (Boston, MA, USA), Harriette Van Spall (Hamilton, CAN), Faiez Zannad (Paris, FRA)

State
Tuesday, December 8, 2026
08:30 -10:30

Statistics Master Class # 1:
SOME PERENNIAL CHALLENGES IN TRIAL DESIGN AND ANALYSIS
Chairpersons: Frank Rockhold (Durham, NC, USA) & Gregg Stone (New York, NY, USA)

In this session, we cover these topical themes:
Per protocol analyses, as usually done, are viewed skeptically as potentially biased, whereas the instrumental variable approach provides greater insight.
Randomized trials often lack power and generalizability, and incorporating external data can enhance both.
The non-inferiority design remains common but can be a cumbersome, underpowered tool asking the wrong question. Is there a better way forward?

Instrumental Variables in Randomized Trials
Robert Yeh (Boston, MA, USA)
David Cohen (Boston, MA, USA)

Discussion

Augmenting Power in Randomized Trials Using External Data
Issa Dahabreh (Boston, MA, USA)
TBD

Discussion

Non-inferiority trials: Their use, misuse, and possible alternatives.
Frank Rockhold (Durham, NC, USA)
Javed Butler (Dallas, TX, USA)

Discussion

State
Tuesday, December 8, 2026
11:00 -13:00

iCVCT # 2
PERCUTANEOUS VENTRICULAR ASSIST DEVICES TRIALS.
HIGH-RISK PCI , CARDIOGENIC SHOCK AND UNANSWERED QUESTIONS
Part #1: Percutaneous Mechanical Circulatory Support Devices for High-Risk PCI
Chairpersons: Mitch Krucoff (Durham, NC, USA) & Philippe Garot (CERC, FRA)

Randomized Evidence Evaluating Percutaneous MCS for High-Risk PCI
Divaka Perera (London, GBR)

MCS for High-Risk PCI – What the Evidence Tells Us
Suzanne Baron (Boston, MA, USA)

Regulatory viewpoint
William Herzog (FDA, USA)

Industry viewpoint
Navin Kapur (Abiomed/JnJ, USA)

Update on Percutaneous Ventricular Assist Devices Academic Research Consortium. Endpoint and other trial design issues.
Jeffrey Popma (CRF, USA)

The CVCT Multi-Stakeholder Think Tank Moderated Debate

PERCUTANEOUS MECHANICAL CIRCULATORY SUPPORT DEVICES FOR HIGH-RISK PCI
Chairpersons: Mitch Krucoff (Durham, NC, USA) & Philippe Garot (CERC, FRA)

Panelists: Suzanne Baron (Boston, MA, USA), Dan Burkhoff (New York, NY, USA), Rafael Cavalcante (Boston Scientific, USA) , Kathleen Fenton (NIH, USA), Philippe Garot (CERC, FRA), William Herzog (FDA, USA), Navin Kapur (Abiomed/JnJ, USA), Mitch Krucoff (Durham, NC, USA), Christina Lalani (Boston, MA, USA), Craig Markovitz (Magenta Medical, ISR), Roxana Mehran (New York, NY, USA) , Divaka Perera (London, GBR), Jeffrey Popma (CRF, USA), Nitin Salunke (Supira Medical, USA), Robert Yeh (Boston, MA, USA), Bram Zuckerman (FDA, USA)

State
Tuesday, December 8, 2026
11:00 -13:00

iCVCT # 2
PERCUTANEOUS VENTRICULAR ASSIST DEVICES TRIALS
Part #2. Mechanical Circulatory Support Devices for Cardiogenic Shock
Chairpersons: Roxana Mehran (New York, NY, USA) & Robert Yeh (Boston, MA, USA)

Benefit/Risk of MCS In Stable Patients: The Critical Difference Defining «High Risk PCI» vs.»SCAI A (Pre-shock) CAD Phenotype
Michell Krucoff (Durham, NC, USA)

Clinical Trial Designs to Support Approval of New Shock Devices
Christina Lalani (Boston, MA, USA)

Pumps and Pills in Parallel: The INTeGRATE Trial in HF-Cardiogenic Shock
Alexandre Mebazaa (Paris, FRA)

Regulatory viewpoint
William Herzog (FDA, USA)

Industry viewpoints
Navin Kapur (Abiomed/JnJ, USA), Craig Markovitz (Magenta Medical, ISR), Nitin Salunke (Supira Medical, USA)

The CVCT Multi-Stakeholder Think Tank Moderated Debate

HIGH-RISK PCI, CARDIOGENIC SHOCK AND UNANSWERED QUESTIONS
Chairpersons: Roxana Mehran (New York, NY, USA) & Robert Yeh (Boston, MA, USA)

Panelists: Suzanne Baron (Boston, MA, USA), Dan Burkhoff (New York, NY, USA), Rafael Cavalcante (Boston Scientific, USA) , Kathleen Fenton (NIH, USA), Philippe Garot (CERC, FRA), William Herzog (FDA, USA), Navin Kapur (Abiomed/JnJ, USA), Mitch Krucoff (Durham, NC, USA), Christina Lalani (Boston, MA, USA), Craig Markovitz (Magenta Medical, ISR), Alexandre Mebazaa (Paris, FRA),Roxana Mehran (New York, NY, USA), Divaka Perera (London, GBR), Jeffrey Popma (CRF, USA), Jon Resar (FDA, USA), Nitin Salunke (Supira Medical, USA), Robert Yeh (Boston, MA, USA)

State
Tuesday, December 8, 2026
14:30 -16:30

iCVCT # 3
PCI WITHOUT PERMANENT CAGING - NEW DEVICES FOR DE NOVO CORONARY ARTERY REVASCULARIZATION
Part 1: WILL A LEAVE-NOTHING-BEHIND STRATEGY FOR DE NOVO PCI IMPROVE LATE OUTCOMES AFTER FIRST DES?
Chairpersons: Donald Cutlip (Boston, MA, USA) & Robert Yeh (Boston, MA, USA)

Coronary disease: have we finally learned whom to revascularize?
Bernard Gersh (Rochester, MN, USA)

Avoiding first DES in favor of a nothing-behind strategy will improve late outcomes after PCI.
Gregg Stone (New York, NY, USA)

Late outcomes after PCI are unlikely to improve with a leave nothing behind strategy.
Ziad Ali (New York, NY, USA)

FDA viewpoint
Lydia Glaw (FDA, USA)

Industry viewpoints
Rafael Cavalcante (Boston Scientific, USA)

Patient viewpoint
Bray Patrick-Lake (Evidation, USA)

The CVCT Multi-Stakeholder Think Tank Moderated Debate
LEAVE-NOTHING-BEHIND STRATEGY
Chairpersons: Donald Cutlip (Boston, MA, USA) & Robert Yeh (Boston, MA, USA)

Panelists: Ziad Ali (New York, NY, USA), Dom Alloco (Shockwave/J&J, USA), Rafael Cavalcante (Boston Scientific, USA), David Cohen (Boston, MA, USA), Roisin Colleran (Galway, IRL), Donald Cutlip (Boston, MA, USA), Andrew Farb (FDA, USA), Philippe Garot (CERC, FRA), Praktiki Gaba (Boston, MA, USA), Lydia Glaw (FDA, USA), Bernard Gersh (Rochester, MN, USA), Roxana Mehran (New York, NY, USA), Bray Patrick-Lake (Evidation, USA), Motasim Sirhan (Elixir Medical, USA), Gregg Stone (New York, NY, USA), Stefan Verheye (Brussels, BEL), Ron Waksman (Washington, DC, USA), Robert Yeh (Boston, MA, USA), Bram Zuckerman (FDA, USA)

State
Tuesday, December 8, 2026
14:30 -16:30

iCVCT # 3
PCI WITHOUT PERMANENT CAGING - NEW DEVICES FOR DE NOVO CORONARY ARTERY REVASCULARIZATION
Part 2: LEAVE LESS BEHIND STRATEGIES: COST, BENEFIT, INNOVATION AND SUSTAINABILITY
Chairpersons: Donald Cutlip (Boston, MA, USA) & Robert Yeh (Boston, MA, USA)

Drug-coated balloons for de novo lesions. Review of current clinical trial designs and future utilization.
Roisin Colleran (Galway, IRL)

Beyond the permanent cage: Can “uncaging devices” overcome the late failure of DES without repeating the bioresorbable-scaffold experience.
Stefan Verheye (Brussels, BEL)

Health system viewpoint – Why Should We Pay for New Balloons/Stents/Scaffolds When DES Are So Affordable
Ron Waksman (Washington, DC, USA)

Industry viewpoints
Dom Alloco (Shockwave/J&J, USA), Motasim Sirhan (Elixir Medical, USA)

The CVCT Multi-Stakeholder Think Tank Moderated Debate

LEAVE-NOTHING VS. LEAVE LESS BEHIND STRATEGIES
Chairpersons: Donald Cutlip (Boston, MA, USA) & Robert Yeh (Boston, MA, USA)

Panelists: Ziad Ali (New York, NY, USA), Dom Alloco (Shockwave/J&J, USA), Rafael Cavalcante (Boston Scientific, USA), David Cohen (Boston, MA, USA), Roisin Colleran (Galway, IRL), Donald Cutlip (Boston, MA, USA), Andrew Farb (FDA, USA), Philippe Garot (CERC, FRA), Lydia Glaw (FDA, USA), Bernard Gersh (Rochester, MN, USA), Roxana Mehran (New York, NY, USA), Bray Patrick-Lake (Evidation, USA), Motasim Sirhan (Elixir Medical, USA), Gregg Stone (New York, NY, USA), Stefan Verheye (Brussels, BEL), Ron Waksman (Washington, DC, USA), Robert Yeh (Boston, MA, USA), Bram Zuckerman (FDA, USA)

State
Tuesday, December 8, 2026
17:00 -19:00

iCVCT # 4
VALVE TRIALS
Part #1 ARE OUR CURRENT TRIAL DESIGNS “FIT FOR PURPOSE”?
Chairpersons : David Cohen (Boston, MA, USA) & Vinod Thourani (Atlanta, GA, USA)

Device vs. device Trials: Considerations for endpoint selection
Chad Kliger (FDA, USA)

Quality of Life is the Main Benefit of TTVI—Why not Make it the Primary Endpoint of Device vs. Device Trials?
Suzanne Arnold (Kansas City, MO, USA)

Statistician viewpoint: Multiple Comparators, Crossover and Bayesian issues
Ben Saville (Austin, TX, USA)

Are Device vs. Device trials even Appropriate?
Juan Granada (New York, NY, USA)

Should Cardiac Surgery be in the Mix? The Case for Trials vs. Surgery
Gorav Ailawadi (Ann Arbor, MI, USA)

Panel Discussion

ARE OUR CURRENT TRIAL DESIGNS “FIT FOR PURPOSE”?
Chairpersons : David Cohen (Boston, MA, USA) & Vinod Thourani (Atlanta, GA, USA)

Panelists: Gorav Ailawadi (Ann Arbor, MI, USA), Suzanne Arnold (Kansas City, MO, USA), Suzanne Baron (Boston, MA, USA), Rishi Chandiramani (Baltimore, MD, USA), David Cohen (Boston, MA, USA), Juan Granada (New York, NY, USA), Kendra Grubb (Medtronic, USA), Aakriti Gupta (New York, NY, USA), Sanjay Kaul (Los Angeles, CA, USA), Chad Kliger (FDA, USA), Michael Mack (Dallas, TX, USA), Roxana Mehran (New York, NY, USA), Mark Reisman (Edwards, USA), Frederic Resnic (Burlington, MA, USA), Ben Saville (Austin, TX, USA) Sreek Vemulapalli (Durham, NC, USA), Vinod Thourani (Atlanta, GA, USA), Changfu Wu (FDA, USA)

State
Tuesday, December 8, 2026
17:00 -19:00

iCVCT # 4
TRICUSPID VALVE INNOVATION
Part #2 THE TVT REGISTRY AT THE CROSSROADS
Chairpersons : David Cohen (Boston, MA, USA) & Vinod Thourani (Atlanta, GA, USA)

The TVT Registry- Lessons from the First 15 Years.
Michael Mack (Dallas, TX, USA)

A View from the Trenches— What I Wish we Had Done Differently.
Sreek Vemulapalli (Durham, NC, USA)

Are EHR-Based Solutions a Viable Alternative?
Frederic Resnic (Burlington, MA, USA)

Industry viewpoints
Kendra Grubb (Medtronic, USA)

Regulatory viewpoint
Changfu Wu (FDA, USA)

Payer viewpoint
Marco Marchetti (AGENAS, IT)

The CVCT Multi-Stakeholder Think Tank Moderated Debate

TRICUSPID VALVE INNOVATION – LESSONS FROM TRIALS AND REGISTRIES
Chairpersons : David Cohen (Boston, MA, USA) & Vinod Thourani (Atlanta, GA, USA)

Panelists: Gorav Ailawadi (Ann Arbor, MI, USA), Suzanne Arnold (Kansas City, MO, USA), Suzanne Baron (Boston, MA, USA), Rishi Chandiramani (Baltimore, MD, USA), David Cohen (Boston, MA, USA), Juan Granada (New York, NY, USA), Kendra Grubb (Medtronic, USA), Aakriti Gupta (New York, NY, USA), Sanjay Kaul (Los Angeles, CA, USA), Chad Kliger (FDA, USA), Michael Mack (Dallas, TX, USA), Marco Marchetti (AGENAS, ITA), Roxana Mehran (New York, NY, USA), Mark Reisman (Edwards, USA), Frederic Resnic (Burlington, MA, USA), Ben Saville (Austin, TX, USA), Sreek Vemulapalli (Durham, NC, USA), Vinod Thourani (Atlanta, GA, USA), Changfu Wu (FDA, USA)

Chinese
Tuesday, December 8, 2026
11:00 -13:00

ESC European Society of Cardiology

ESC-CVCT JOINT SESSION
LBCT 3
Artificial Intelligence and digital therapeutics - Arrhythmia
Chairpersons: Rahul Aggarwal (Boston, MA, USA) & Tina Baykaner (Stanford, CA, USA)

3.a Artificial Intelligence and digital therapeutics (presentation times 8 min)

Use of artificial intelligence in the electronic health record to ascertain outcomes, estimate treatment effects, and conduct 25-year follow-up of the COURAGE trial
N Butala1,*, N Rahman2, N Murali2, S Cave3, S Ayandeh4, M Plomondon5, J Cunningham6, W Weintraub7, R Yeh8, W Boden9, S Waldo1
1Rocky Mountain Regional VA Medical Center - DENVER (United States), 2Denver Research Institute - Denver (United States), 3VA Clinical Assessment, Reporting, and Tracking Program - Washington, DC (United States) - Washington, DC (United States), 4VA Office of Research and Development - Washington, DC (United States), 5VA Clinical Assessment, Reporting, and Tracking Program - Washington, DC (United States), 6Brigham and Women's Hospital - Boston (United States), 7Brigham and Women's Hospital - Washington, DC (United States), 8Beth Israel Deaconess Medical Center - Boston (United States), 9VA Boston Healthcare System - Boston (United States)

Large language model–based adjudication of specific causes of death in cardiovascular clinical trials
A Cruz-Solbes1,*, R Helseth2, M Ruppert3, P Marti-Castellote1, S Badrouchi4, B Claggett1, S Khurshid5, P Ellinor5, J Ho6, M Pfeffer1, P Jhund7, A Desai1, J Mcmurray7, S Solomon1, J Cunningham1
1Brigham and Women's Hospital - Boston (United States), 2Oslo Center for Clinical Heart Research - Oslo (Norway), 3Semmelweis University - Budapest (Hungary), 4Charles Nicolle University Hospital - Tunis (Tunisia), 5Mass General Brigham - Boston (United States), 6Beth Israel Deaconess Medical Center - Boston (United States), 7University of Glasgow - Glasgow (United Kingdom)

AI-enabled ECG for hypertension and hypertensive heart disease: development, external validation, and prognostic value versus cardiac biomarkers in SPRINT and ACCORD
A Pandey1,*, M Usman2, S Reddy N3, S Mendiratta4, A Anto4, S Asfahan4, W Ip5, R Suratekar4, A Armoundas6, E Priest7, E Brittain8, V Somers9, Z Zoghby9, J Oh9, P Noseworthy9, A Attia9, D Rushlow9, A Desai10, F Lopez-Jimenez9, J Butler7, S Shah11, S Awasthi12, I Meredith13
1University of Michigan - Ann Arbor (United States), 2University of Texas Southwestern Medical Center - Dallas (United States), 3Anumana - Bengaluru (India), 4Anumana Inc - Bengaluru (India), 5Anumana Inc - Cambridge (United States), 6Massacusetts General Hospital - Charlestown (United States), 7Baylor Scott and White Research Institute - Dallas (United States), 8Vanderbilt University - Nashville (United States), 9Mayo Clinic - Rochester (United States), 10Brigham and Women's Hospital - Boston (United States), 11Northwestern University - Chicago (United States), 12Anumana - Cambridge (United States), 13Monash University - Clayton (Australia)

Large Language Models to Distinguish Explained From Actionable Gaps in Guideline-Directed Therapy for Chronic Kidney Disease
S. Badrouchi1,*, K. B. Lo1, R. Helseth1, A. S. Cruz-Solbes1, P. M. Marti-Castellote1, B. L. Claggett1, P. T. Ellinor2, B. L. Neuen3, M. Vaduganathan1, S. D. Solomon1, M. M. Mcgrath1, F. R. Mc Causland1, J. W. Cunningham1,*
1Brigham and Women's Hospital - Boston (United States), 2Brigham and Women's Hospital (United States), 3George Institute for Global Health - Sydney (Australia)

Effect of Apple Watch vs Control Device on Patient-Quality of Life: Results from the Heart Watch Pragmatic Randomized Controlled Trial
S Dhruva1,*, J Akar2, A Beatty1, A Deshmukh3, J Freeman2, R Ghosh2, M Grewal2, J Hummel2, M Jeffery3, C Knepper3, P Noseworthy3, J Piccini4, E Pinci2, J Ritchie2, N Shah5, S Snow4, S Vemulapalli4, J Ross2
1UCSF School of Medicine - San Francisco (United States), 2Yale School of Medicine - New Haven (United States), 3Mayo Clinic - Rochester (United States), 4Duke Clinical Research Institute - Durham (United States), 5University of Texas, Austin - Austin (United States)

Discussant (10 min)
Rohan Khera (New Haven, CT, USA)

Q&A (10min)

Chinese
Tuesday, December 8, 2026
11:00 -13:00

ESC European Society of Cardiology

ESC-CVCT JOINT SESSION
LBCT 3
Artificial Intelligence and digital therapeutics - Arrhythmia
Chairpersons: Rahul Aggarwal (Boston, MA, USA) & Tina Baykaner (Stanford, CA, USA)

3.b Arrhythmia (presentation times 8 min)

Risk of Stroke and TIA With Pulsed Field Compared With Radiofrequency Ablation for Atrial Fibrillation
E.G. Ferro1,*, A. D'avila1, M. Reynolds1, D. Villareal1, J. Nelson1, J. Yoon1, S. Vu1, A. Nallaparaju1, A. Locke1, T. Maher1, S. Yang1, P. Tung1, R. Yeh1, P. Zimetbaum1, J. Waks1, D. Kramer1
1Beth Israel Deaconess Medical Center - Boston (United States)

Rhythm control and quality of life in atrial fibrillation: a post-hoc analysis of the PVI-SHAM-AF trial
P Haag1,*, D Petroff1, M Bacak1, M Forkmann2, T Gaspar3, M Neef1, E Eckardt4, U Laufs1, G Hindricks5, N Dagres5, R Wachter1
1 - Leipzig (Germany), 2 - Coburg (Germany), 3 - Dresden (Germany), 4 - Münster (Germany), 5 - Berlin (Germany)

Direct oral anticoagulants for stroke prevention in patients with atrial fibrillation and a CHA2DS2-VA score of 1: a study-level meta-analysis of the SINGLE-AF, BRAIN-AF and AVERROES randomized trials
AP Benz1,*, D Kim2, L Rivard3, WF Mcintyre1,*, JW Eikelboom1, JS Healey1, B Joung4
1Population Health Research Institute, McMaster University - Hamilton (Canada), 2Division of Cardiology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine - Seoul (Korea, Republic of), 3Department of Medicine, Université de Montréal - Montréal (Canada), 4Division of Cardiology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine - Seoul (Korea, Republic of) - Seoul (Korea, Republic of)

EQ-5D-3L functional dimensions define patient-reported phenotypes for risk stratification and response to echocardiographic screening: a secondary analysis of the OPT-PACE trial.
F. Varian1, 2,*, T. May1, S. Straw1, 2, J. Gierula1, J. Lowry1, N.A. Samad1, O.I. Brown1, 2, M. Mcginlay1, R. Cubbon1, M.T. Kearney1, K.K. Witte1, M.F. Paton1, 2
1University Of Leeds - Leeds (United Kingdom), 2Leeds Teaching Hospitals Nhs Foundation Trust

Discussant (10 min)
Paulus Kirchhof (Hamburg, GER)

Q&A (10min)

Chinese
Tuesday, December 8, 2026
14:30 -16:30

ESC European Society of Cardiology

ESC-CVCT JOINT SESSION
LBCT 4
Atherosclerosis and Lipids
Chairpersons: Pamela Taub (San Diego, CA, USA) & Andre Zimerman (Porto Allegre, BRA)

Session 1 (presentation times 8 min)

Efficacy and Safety of Enlicitide, an Oral PCSK9 Inhibitor, in Statin-Intolerant Participants on No Background Statin Therapy in the CORALreef Lipids Trial
A Navar1,*, M Zhou2, P Banka2, A Catapano3, E Stroes4, W Zhang2, L Gellis2, C Ballantyne5
1Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center - Dallas,TX (United States), 2Merck & Co., Inc. - Rahway, NJ (United States), 3University of Milan, IRCCS MultiMedica - Milan (Italy), 4Department of Vascular Medicine, Amsterdam UMC, University of Amsterdam - Amsterdam (The Netherlands), 5Section of Cardiovascular Research, Department of Medicine, Texas Heart Institute at Baylor College of Medicine - Houston, TX (United States)

Bivalent RSV Prefusion F Protein-based Vaccine and Cardiovascular Outcomes in a General Adult Population: A Prespecified Analysis of the DAN-RSV Randomized Trial
M. Pareek1,*, M. Lassen1, M. Yafasov1, S. Christensen1, N. Johansen1, A. Rudolph2, C. Rodriguez-Tenreiro-Sanchez3, K. Skaarup1, D. Modin1, B. Claggett4, C. Larsen5, L. Larsen6, L. Wiese7, M. Dalager-Pedersen8, M. Lindholm7, A.M. Jensen1, M. Dons1, K. Bernholm1, F. Davidovski1, L. Duus1, C. Ottosen1, A. Nielsen1, J. Borchsenius1, C. Espersen1, G. Kose1, F. Fussing1, I. Lenz1, J. Christensen1, J. Simonsen1, M. Afzal1, K. Bartholdy1, A. Langhoff1, L. Kober9, S. Solomon4, J.U. Jensen1, C. Martel10, I. Gine-Vazquez3, C. Duran-Parrondo3, M. Pineiro-Sotelo3, M. Cribeiro-Gonzalez3, M. Conde-Pajaro3, S. Miras-Carballal3, J.M. Gonzalez-Perez3, B. Gessner2, N. Aliabadi2, C. Schwarz2, M. Skovdal2, L. Moulton2, P. Zhang2, V. Lopez-Gomez2, S. Welsh2, L. Anatale-Tardiff2, A. Cane2, K. Hayford2, F. Martinon-Torres3, E. Begier3, T. Biering-Sorensen1
1Copenhagen University Hospital-Herlev And Gentofte - Hellerup (Denmark), 2Pfizer - New York (United States), 3Instituto De Investigación Sanitaria De Santiago De Compostela - Santiago De Compostela (Spain), 4Brigham And Women's Hospital - Boston (United States), 5Aarhus University Hospital - Aarhus (Denmark), 6Odense University Hospital - Odense (Denmark), 7Zealand University Hospital - Roskilde (Denmark), 8Aalborg University Hospital - Aalborg (Denmark), 9Copenhagen University Hospital-Herlev And Gentofte - Herlev (Denmark), 10Statens Serum Institut - Copenhagen (Denmark)

Personalized edoxaban dosing guided by a validated exposure-based risk model in ENGAGE AF-TIMI 48: value, who benefits, and implications for dosing and trials
C. Michael Gibson1, Cathy Chen2, Jacqueline Buros-Novik3, Eric Novik3,4, Elliott M. Antman5, Robert P. Giugliano5, Martin Unverdorben6
1Baim Institute for Clinical Research, Harvard Medical School, Boston, Massachusetts, USA; 2Markham, ON, Canada; 3Generable, New York, New York, USA; 4New York University, New York, New York, USA; 5TIMI Study Group, Cardiovascular Division, Brigham and Women's Hospital, Department of Medicine, Harvard Medical School, Boston, Massachusetts, USA; 6NNN, Pottstown, PA, USA

Targeting NLRP3 Inflammasome Signalling in Clonal Haematopoiesis and Coronary Artery Disease: A Randomised Phase 2a Trial
M. Von Scheidt1,*, J.C. Tardif2, S. Cremer3, J.B. Heimlich4, C. O'donnell5, W. Koenig1, A.G. Bick4, M.M. Mendelson6
1Tum University Hospital German Heart Centre - Munich (Germany), 2Montreal Heart Institute - Montreal (Canada), 3Goethe University Frankfurt - Frankfurt (Germany), 4Vanderbilt University - Nashville (United States), 5Novartis Biomedical Research - Cambridge (United States), 6Novartis Biomedical Research - Basel (Switzerland)

Effects of siRNA-mediated profound FXI inhibition on ex vivo coagulation and platelet function in patients with chronic coronary artery disease: vortosiran phase 2a trial
S Svedlund1,*, A Gabrielsen2,*, J Wikström2, S Ueckert2, C Nilsson2, AC Egnell2, C Jr. Pollack2, S Gao2, J I. Weitz3, LM Gan1, CSP Lam4
1Ribocure Pharmaceuticals AB, Mölndal, Sweden / Suzhou Ribo Life Science Co Ltd, Kunshan City, Jiangsu, China. Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden - Mölndal (Sweden), 2Ribocure Pharmaceuticals AB, Mölndal, Sweden / Suzhou Ribo Life Science Co Ltd, Kunshan City, Jiangsu, China - Mölndal (Sweden), 3Department of Medicine, McMaster University, Hamilton, Ontario, Canada. - Hamilton (Canada), 4National Heart Centre Singapore & Duke-National University of Singapore, Singapore - Singapore (Singapore)

Discussant: 10 min
Wolfgang Koenig (Munich, GER)

Chinese
Tuesday, December 8, 2026
14:30 -16:30

ESC-CVCT JOINT SESSION
LBCT 4
Atherosclerosis and Lipids
Chairpersons: Pamela Taub (San Diego, CA, USA) & Andre Zimerman (Porto Allegre, BRA)

Session 2 (presentation times 8 min)

Heterogeneity of lipoprotein(a) distributions across cardiovascular phenotypes: A multi-cohort comparison with the general population
N Arnold1,*, A Goßling1, B Bay1, Ch Blaum1, R Twerenbold1, J Neumann1, N Sörensen1, S Blankenberg1, FJ Brunner1
1University Heart and Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany - Hamburg (Germany)

Lipoprotein(a) Composition and Coronary Plaque Phenotypes: Insights from the Essence-TIMI 73b Trial
S Tsimikas1,*, A Leikas1, X Yang1, L Lin1, V Alexander2, E Waldman2, D Li2, T Prohaska2, B Bergmark3
1UCSD - La Jolla (United States), 2Ionis - Carlsbad (United States), 3Brigham aCarlsbadnd Women's - Boston (United States)

Beyond Lp(a) Concentration: Multidomain Phenotyping of Recurrent Cardiovascular Risk and Modeled Lp(a) Lowering in Established Coronary Artery Disease
NA Arnold1,*, AG Goßling1, BB Bay1, CB Blaum1, SB Blankenberg1, FB Brunner1
1University Heart and Vascular Center Hamburg, University Medical Center Hamburg-Eppendorf, Hamburg, Germany - Hamburg (Germany)

Lipoprotein (a) is associated with impaired natural killer (NK) cell function and impaired mitochondrial homeostasis
Y. Baumer1,*, A. Saurabh1, L.G. Mendelsohn1, M.R. Andrews1, T.M. Powell-Wiley1
1Nhlbi - Bethesda (United States)

High Prevalence of Coronary Inflammation Despite Low hsCRP in Clinically Stable Post-Myocardial Infarction Patients: Findings from the FORTIFY trial
C Farina1,*, W Lu1, A Gille1, K Melvin1, J Nilsson1, 2, T Villines3, G Schwartz4, C Shirodaria5, 6, C Antoniades5, 7, P Libby8, 9
1Abcentra (United States), 2Lund University, 3University of Virginia School of Medicine (United States), 4University of Colorado School of Medicine, 5Caristo Diagnostics (United States), 6Fortrea Clinical Research Unit Limited, 7University of Oxford, 8Harvard Medical School (United States), 9Mass General Brigham

Discussant (10 min)
Robert Rosenson (New York, NY, USA)

Q&A (10min)

Chinese
Tuesday, December 8, 2026
17:00 -19:00

PULMONARY HYPERTENSION NEXT FRONTIERS

Chairpersons: Mardi Gomberg-Maitland (Washington, DC) & Bradley Maron (Circulation, USA)

Concept of urgency in treatment of patients with pulmonary hypertension
Mardi Gomberg-Maitland (Washington, DC, USA)

Survival discrepancy between PAH patients eligible for clinical trials and clinical reality
Mark Toshner (Cambridge, GBR)

Heterogeneity of treatment effect in patients with PAH and co-existing mild lung diseases participating in randomized clinical trials
Steve Kawut (Philadelphia, PA, USA)

Remission as a goal in PAH
Jason Weatherald (Edmonton, CA)

Predictors of pulmonary hypertension in patients with interstitial lung disease
Corey Ventetuolo (Providence, RI, USA)

Pulmonary hypertension associated with interstitial lung diseases: Is it time to consider a morbidity and mortality primary endpoint?
Oksana Shlobin (Falls Church, VA, USA)

Pulmonary hypertension associated with left heart disease: Is it time to consider a morbidity and mortality primary endpoint?
Jean-Luc Vachiéry (Brussels, BE)

Investigator Viewpoints
Hap Farber (Boston, MA, USA)
Sandeep Sahay (Houston, TX, USA)

Patient Viewpoint
Coleen Brunetti (Pulmonary Hypertension Association, USA)

Industry Viewpoints
Mahesh Patel (Merck, USA), Carlos Sanmarco (Pulmovant, USA)

The CVCT Multi-Stakeholder Think Tank Moderated Debate

PULMONARY HYPERTENSION NEXT FRONTIERS

Chairpersons: Mardi Gomberg-Maitland (Washington, DC) & Bradley Maron (Circulation, USA)

Panelists: Coleen Brunetti (Pulmonary Hypertension Association), Kelly Chin (Dallas, TX, USA), Chris Cabel (Inhibikase, USA), Bjorn Dahlof (Cereno, SWE), Hap Farber (Boston, MA, USA), Mardi Gomberg-Maitland (Washington, DC), Anna Hemnes (Nashville, TN), Nick Hill (Boston, MA, USA), Marc Humbert (Paris, FRA), Steve Kawut (Philadelphia, PA, USA), Bradley Maron (Circulation, USA), Vallerie McLaughlin (Ann Arbor, MI, USA), Mahesh Patel (Merck, USA), Iona Preston (Boston, MA, USA), Mitch Psotka (FDA, USA), Franck Rahaghi (United Therapeutics, USA), Yogesh Reddy (Rochester, MN, USA), Sandeep Sahay (Houston, TX, USA), Carlos Sanmarco (Pulmovant, USA), Oksana Shlobin (Falls Church, VA, USA), Olivier Sitbon (Paris, FRA), Derek Solum (United Therapeutics, NC), Mark Toshner (Cambridge, GBR), Anjali Vaidya (Philadelphia, PA, USA), Jean-Luc Vachiéry (Brussels, BE), Corey Ventetuolo (Providence, RI), Jason Weatherald (Edmonton, CA), Rainer Zimmermann (Gossamer, USA)

Ballroom
Tuesday, December 8, 2026
08:30 -10:30

ACC-CVCT JOINT SESSION
AI MASTER CLASS 3
FROM BORROWED TO BUILT: HOW FAR CAN WE GO WITHOUT ENROLLING A PATIENT?
EMULATING, BORROWING, GENERATING AI AND SIMULATING TRIAL DATA
CAN REGULATORS AND CLINICIANS STILL TRUST IT?
Chairpersons: Rohan Khera (New Haven, CT, USA) & Harlan Krumholz (JACC, USA)

Every control arm we randomize costs money, costs time, and exposes patients to a treatment we already believe is inferior. Four distinct technologies now propose to shrink or replace it: emulating trials from routinely collected data, borrowing control patients from completed trials, generating patients with AI, and simulating them from physiology.
Each rests on a different assumption and each fails in a different way — exchangeability for the first two, model fidelity for the third, verification and validation for the fourth. This session climbs the four rungs in order and asks, at each one, what a regulator has actually accepted and what remains a promise.

Framework for Regulatory/Community Acceptance of AI-Generated Data: Context of Use, Model Influence, and Decision Consequence
Jonathan Cunningham (Boston, MA, USA)

From replicating trial findings with healthcare data to robust trial-anchored non-randomized evidence.
Sebastian Schneeweiss (Boston, MA, USA)

Real patients, borrowed: external and synthetic control arms
Miguel Hernán (Boston, MA, USA)

Digital Twins and In Silico Control Arms: When Are They Valid?
Blanca Rodriguez (Oxford, GBR)

Simulated patients: in silico clinical trials
Emmanuelle Pham (NovoInSilico, FRA)

EHR-based eligibility surveillance and automated patient recruitment
Michael Gibson (Boston, MA, USA)

AI-Assisted clinical trials screening
Alexander Blood (AIwithCare, USA)

Industry Perspective
Alexandra Goncalves (BMS, USA)

Regulatory Perspective
TBD
TBD (FDA)

The CVCT Multi-Stakeholder Think Tank Moderated Debate

WITHIN 10 YEARS, AI- AND MODEL-GENERATED EVIDENCE WILL BE ACCEPTED AS EQUIVALENT TO TRADITIONAL TRIAL EVIDENCE — AND THIS IS A GOOD THING
Chairpersons : Rohan Khera (New Haven, CT, USA) & Harlan Krumholz (JACC, USA)

Panelists: Alexander Blood (AIwithCare, USA), Jonathan Cunningham (Boston, MA, USA), Viral Gandhi (Aviga Health, USA), Michael Gibson (Boston, MA, USA), Alexandra Goncalves (BMS, USA), Miguel Hernán (Boston, MA, USA), Rohan Khera (New Haven, CT, USA), Harlan Krumholz (JACC, USA), Bakul Patel (Google, USA), Emmanuelle Pham (NovoInSilico, FRA), Blanca Rodriguez (Oxford, GBR), Sebastian Schneeweiss (Boston, MA, USA)

Ballroom
Tuesday, December 8, 2026
11:00 -13:00

Bayesian Statistics Masterclass #2
BAYESIAN STATISTICS IN CARDIOVASCULAR TRIALS: FOUNDATIONS, GUIDANCE, AND EVOLVING PERSPECTIVES
Chairpersons: Frank Harrell (Nashville, TN, USA) & Norman Stockbridge (S&S Consulting, USA)

Bayesian statistics is gaining renewed attention in cardiovascular trials, offering a framework for integrating prior knowledge, accumulating evidence, and supporting clinically meaningful decision-making. This masterclass will introduce Bayesian concepts for clinicians, explore how Bayesian thinking differs from traditional frequentist approaches, and examine how it reframes evidence thresholds, multiplicity, and interpretation of trial results. It will also review the draft Bayesian guidance and consider what doors it may open for trial design, regulatory considerations, and future cardiovascular evidence generation. The session will close with reflections on how views of Bayesian methods have evolved, from skepticism to recognition of their potential role in modernizing cardiovascular trials.

A Primer on What Bayes Offers to Randomized Clinical Trials
Scott Berry (Berry Consultants, USA)

Discussion

The Essence of Bayesian Statistics
Frank Harrell (Nashville, TN, USA)

Discussion

A Review of the Draft Bayesian Guidance and its Impacts
James Travis (FDA, USA)

Discussion

Evolving Views on Bayes
Norman Stockbridge (S&S Consulting, USA)

Discussion

The CVCT Multi-Stakeholder Think Tank Moderated Debate
UNDERSTANDING BAYESIAN STATISTICS
Chairpersons: Frank Harrell (Nashville, TN, USA) & Norman Stockbridge (S&S Consulting, USA)

Panelists: Scott Berry (Berry Consultants, USA), Frank Harrell (Nashville, TN, USA), Norman Stockbridge (S&S Consulting, USA), James Travis (FDA, USA)

Ballroom
Tuesday, December 8, 2026
14:30 -16:30

Statistics Masterclass #3
BAYESIAN DESIGNS IN ACTION: LEARNING, BORROWING, AND ADAPTING
Chairpersons: Scott Berry (Berry Consultants) & Graeme Hickey (Medtronic, USA)

Bayesian methods offer a flexible framework for clinical trial design, allowing studies to learn and adapt as evidence accumulates. Beyond familiar uses such as interim monitoring, early stopping, and sample size selection, Bayesian approaches can support borrowing from historical or external data, adaptive enrichment of trial populations, and more flexible approaches to complex or multiple endpoints, while also offering powerful tools for earlier-phase questions such as dose selection. Through real-world trial examples, this masterclass will illustrate how Bayesian designs can use accumulating evidence to guide trial decisions, focus enrollment on populations most likely to benefit, and create more flexible and efficient cardiovascular trials.

SPYRAL HTN: Dynamic Discounting in Practice
Graeme Hickey (Medtronic, USA)

Discussion

PM RESPONDER-HF: Fixed Borrowing with a Hierarchical Endpoint
Amy Crawford (Berry Consultants, USA)

Discussion

ENRICH: Adaptive Enrichment of the Trial Population
Ben Saville (Austin, TX, USA)

Discussion

Anticoagulation in COVID-19: An Adaptive Multiplatform Trial
Patrick Lawler (Montreal, CAN)

Discussion

Palm court
Wednesday, December 9, 2026
08:00 -10:00

CARDIOVASCULAR GENE THERAPY TRIALS: WHY IS TRANSLATION SO DIFFICULT?
Chairpersons : Deborah Ascheim (Boston, MA, USA) & Andrew Baker (Edinburgh, GBR)

Contrasting irreversible genomic intervention with the conservative cardiovascular outcomes trial culture.
Deborah Ascheim (Boston, MA, USA)

What duration is sufficient for approval in the context of durability—reversibility of expression?
Roger Hajjar (Boston, MA, USA)

Gene therapy for prevention of vein graft failure
Andrew Baker (Edinburgh, GBR)

Genetic Therapies for Inherited Life-Threatening Arrhythmias: From CPVT to LQT8
Silvia Priori (Pavia, ITA)

Gene therapy for rare diseases (5min each)

Danon Disease and Rare Disease Clinical Translation
Barry Greenberg (San Diego, CA, USA)

Rare Cardio-Neuro Disorders and Precision Cardiomyopathies
Alessia Argirò (Florence, ITA)

LMNA Cardiomyopathy and Mechanobiology
Monica Shah (Nuevocor, Singapore, SGP)

Targeting Friedreichs Cardiomyopathy, One Part of a Multisystem Approach
Gabriel Brooks (Solidbio, USA)

Challenges in Rare Cardiovascular Disease. How much evidence-flexibility is acceptable?
Janet Wittes (Wittes LLC, USA)

Patient Perspectives and Acceptance of an irreversible therapy.
Pieter Glijnis (Phospholamban Foundation, NED)

The CVCT Multi-Stakeholder Think Tank Moderated Debate

CREATIVE CLINICAL TRIALS SOLUTIONS FOR ADVANCING GENE THERAPY
Chairpersons: Deborah Ascheim (Boston, MA, USA) & Andrew Baker (Edinburgh, GBR)

Panelists : Alessia Argirò (Florence, ITA), Deborah Ascheim (Boston, MA, USA), Andrew Baker (Edinburgh, GBR), Gabriel Brooks (Solidbio, USA), Barry Greenberg (San Diego, CA, USA), Pieter Glijnis (Phospholamban Foundation, NED), Roger Hajjar (Boston, MA, USA), Monica Shah (Nuevocor, SGP), Silvia Priori (Pavia, ITA), Janet Wittes (Wittes LLC, USA)

Palm court
Wednesday, December 9, 2026
10:30 -13:30

THE NEXT GENERATION OF CARDIOVASCULAR GENETIC MEDICINE
Part 1
Chairpersons: Roger J. Hajjar (Boston, MA, USA) & Seppo Ylä-Herttuala (Kuopio, FIN)

Where Cardiovascular Gene Therapy Becomes Clinical Reality.

To this purpose, the CVCT Gene Therapy Trials sessions will explore the transition from first-generation AAV cardiac gene therapy toward scalable cardiovascular genetic medicine. This includes
•Convergence of gene therapy, gene editing, RNA therapeutics, and engineered delivery systems
•Rare monogenic cardiomyopathies versus broad, high-prevalence heart failure indications.
•Clinical trial design evolution in advanced therapeutics
•Regulatory acceleration pathways and “plausible mechanism” frameworks
•Cardiovascular inflammation, fibrosis, and precision endotyping
•Next-generation vector engineering and repeat dosing strategies
•Real-world translational lessons from active clinical programs
•The emergence of gene editing in cardiovascular disease

Opening Perspective. Cardiovascular Genetic Medicine Has Entered Its Second Era
Roger Hajjar (Boston, MA, USA)

Disease Mechanisms and Precision Endotyping.
Victoria Parikh (Stanford, CA, USA)

Cardiac Angiogenesis and Therapeutic Vascular Gene Transfer
Seppo Ylä-Herttuala (Kuopio, FIN)

Cardiac Regeneration in the Clinic
James Martin (Dallas, TX, USA)

PART 1 DISCUSSION

Panelists: Greg Aubert (Lexeo Therapeutics, USA), Narinder Bhalla (Lexeo Therapeutics, USA), Gabriel Brooks (Solid Biosciences, USA), Kevin Costa (Novoheart, CAN), Roger Hajjar (Boston, MA, USA), Kiyotake Ishikawa (New York, NY, USA), Kiyotake Ishikawa (New York, NY, USA), James Kim (Medera, USA), James Martin (Dallas, TX, USA), Megha Kaushal (FDA, USA), Victoria Parikh (Stanford, CA, USA), Christina Quarta (Alexion, USA) Luke Roberts (Bayer, GER), Lothar Roessig (AskBio, GER), Whit Tingley (Tenaya Therapeutics, USA), Seppo Ylä-Herttuala (Kuopio, FIN)

Palm court
Wednesday, December 9, 2026
10:30 -13:30

THE NEXT GENERATION OF CARDIOVASCULAR GENETIC MEDICINE
PART 2 : DELIVERY: ARE WE TESTING THE GENE OR THE PROCEDURE? OUTCOMES MAY DEPEND MORE ON DELIVERY SUCCESS THAN BIOLOGICAL CONSTRUCT QUALITY
Chairpersons: Roger J. Hajjar (Boston, MA, USA) & Seppo Ylä-Herttuala (Kuopio, FIN)

Advanced Cardiac Gene Delivery Platforms
Kiyotake Ishikawa (New York, NY, USA)

Cardiac gene delivery and next-generation capsids.
Gabriel Brooks (Solid Bio, USA)

Precision cardiac gene delivery & Hemodynamic Endpoints in heart failure
James Kim (Medera, USA)

Human Engineered Tissue and IND-Enabling Translation
Kevin Costa (Novoheart, USA)

Neutralizing Antibodies and the GENEPHIT Experience
Luke Roberts (Bayer, GER)

Large-Scale Translation of Cardiovascular Gene Therapy
Lothar Roessig (Askbio, GER)

Hypertrophic Cardiomyopathy Programs
Whit Tingley (Tenaya Therapeutics, USA)

BAG3 Cardiomyopathy and the DCM-RESTORE Trial
Jonathan Lu (Alexion, USA)

Friedreich Ataxia Cardiomyopathy and Rare Disease Translation
Greg Aubert (Lexeo Therapeutics, USA)

Regulatory Viewpoints
Megha Kaushal (FDA, USA)
Maritza McIntyre (Advanced Therapies Partners, MD, USA)

The CVCT Multi-Stakeholder Think Tank Moderated Debate

GENE THERAPY TRANSLATABILITY AND READINESS FOR CLINICAL STAGE
Chairpersons: Roger J. Hajjar (Boston, MA, USA) & Seppo Ylä-Herttuala (Kuopio, FIN)

Panelists: Greg Aubert (Lexeo Therapeutics, USA), Narinder Bhalla (Lexeo Therapeutics, USA), Gabriel Brooks (Solid Biosciences, USA), Kevin Costa (Novoheart, CAN), Roger Hajjar (Boston, MA, USA), Kiyotake Ishikawa (New York, NY, USA), Megha Kaushal (FDA, USA), James Kim (Medera, USA), Jonathan Lu (Alexion, USA), Maritza McIntyre (Advanced Therapies Partners, MD, USA), James Martin (Dallas, TX, USA), Victoria Parikh (Stanford, CA, USA), Luke Roberts (Bayer, GER), Lothar Roessig (AskBio, GER), Whit Tingley (Tenaya Therapeutics, USA), Seppo Ylä-Herttuala (Kuopio, FIN)

Palm court
Wednesday, December 9, 2026
14:30 -16:30

ELECTROPHYSIOLOGY WILL BE PART OF STROKE PREVENTION IN 2030
Chairpersons: Paulus Kirchhof (Hamburg, GER) & Ken Mahaffey (Stanford, CA, USA)

AF Burden and Stroke Risk: Can we measure more to treat less?
Lindsey Rosman (Chicago, IL, USA)

EAST-AFNET 4, OCEAN, ALONE, OPTION: Is rhythm control a stroke-prevention therapy?
Jason Andrade (Vancouver, CAN)

Debate: "Ready or Reckless: Are left atrial occluders a valid replacement for oral anticoagulation?"
PRO: Oussama Wazni (Cleveland, OH, USA)
CON: Atul Verma (Hamilton, CAN)

Better stroke prevention with novel drugs: Factor XI antagonists for stroke prevention
Ken Mahaffey (Stanford, CA, USA)

Anti-vWF aptamers and their antidotes for thromboembolic stroke
Shahid Nimjee (Basking Biosciences, USA)

The 'EP Collaboratory' proposal: addressing systemic challenges in clinical trials
Paul Wang (Stanford, CA, USA)

NIH Viewpoint
Patrice Desvigne-Nickens (NIH/NHLBI, USA)

Industry Viewpoint: "Can Industry Build Comparative Evidence Without Killing Innovation?"
Greg Michaud (JnJ, USA)

Industry Viewpoint: "Beyond Anticoagulation: A Biotech Perspective on Residual Stroke Risk in AF"
David Gutstein (Regeneron, USA)

Industry Viewpoint: "Rhythm control and LAAO. A Medtech perspective on stroke prevention"
Kenneth Stein (Boston Scientific, USA)

Patient Viewpoint: "Stroke and bleeds: What matters for AF patients"
Trudie Lobban (London, GBR)

The CVCT Multi-Stakeholder Think Tank Moderated Debate

HOW ELECTROPHYSIOLOGY MAY BE PART OF STROKE PREVENTION IN 2030?
Chairpersons: Paulus Kirchhof (Hamburg, GER) & Ken Mahaffey (Stanford, CA, USA)

Panelists : Jason Andrade (Vancouver, BC, CAN), Patrice Desvigne-Nickens (NIH/NHLBI, USA), David Gutstein (Regeneron, USA), Paulus Kirchhof (Hamburg, DEU), Trudie Lobban (London, GBR), Kenneth Mahaffey (Stanford, CA, USA), Greg Michaud (JnJ, USA), Shahid Nimjee (Basking Biosciences, USA), Yogesh Reddy (Rochester, MN, USA), Lindsey Rosman (Chicago, IL, USA), Kimberly Selzman (FDA, USA), Kenneth Stein (Boston Scientific, USA), Atul Verma (Hamilton, CAN), Oussama Wazni (Cleveland, OH, USA), Paul Wang (Stanford,CA, USA)

East
Wednesday, December 9, 2026
08:00 -10:30

HEART FAILURE MEETS ELECTROPHYSIOLOGY: THE QUESTIONS THAT WON'T GO AWAY
Chairpersons: Javed Butler (Dallas, TX, USA) & Tina Baykaner (Stanford, CA, USA)

AF ablation outcome trials: The EP community is growing up
Emma Svennberg (Stockholm, SWE)

Debate: "AF ablation in HFrEF: The question is answered"!
PRO: Christian Sohns (Hannover, GER)
CON: Mark Petrie (Glasgow, GBR)

Bidirectional effects of cardiometabolic drugs on atrial and ventricular function.
Anne-Christine Ruwald (Copenhagen, DK)

Beyond the Primary Endpoint: Can Atrial Fibrillation Be Better Tracked in Heart Failure Trials?
Nicolas Girerd (Nancy, FRA)

AF burden and heart failure trajectories: Known unknowns.
Paulus Kirchhof (Hamburg, GER)

Industry Viewpoint: "Measuring More, Treating Smarter": Industry View of HF–EP Trial Design"
Nirav Patel (Medtronic, USA)

Industry Viewpoint: Entresto and Beyond: Reimagining Disease Modification Across the HF–AF Continuum
Steve Lubitz (Novartis, USA)

Industry Viewpoint: "Connecting HF and AF: A Pharma Perspective on Anticoagulation, Cardiorenal Protection, and Trial Design"
Maria Borentain (Bayer, GER)

The CVCT Multi-Stakeholder Think Tank Moderated Debate

ROADMAP FOR HEART FAILURE & ELECTROPHYSIOLOGY TRIALISTS COLLABORATIONS
Chairpersons: Javed Butler (Dallas, TX, USA) & Tina Baykaner (Stanford, CA, USA)

Panelists : Tina Baykaner (Stanford, CA, USA), Maria Borentain (Bayer, GER), Javed Butler (Dallas, TX, USA), Kieran Docherty (Glasgow, GBR), Nicolas Girerd (Nancy, FRA), Paulus Kirchhof (Hamburg, GER), Steve Lubitz (Novartis, USA), Nirav Patel (Medtronic, USA), Mark Petrie (Glasgow, GBR), Anne-Christine Ruwald (Copenhagen, DNK), Christian Sohns (Hannover, GER), Emma Svennberg (Stockholm, SWE)

East
Wednesday, December 9, 2026
10:30 -13:30

CRF THT TECHNOLOGY AND HEART FAILURE THERAPEUTICS

CVCT-THT JOINT SYMPOSIUM
DEVICE THERAPIES FOR HEART FAILURE
SLOW DEVELOPMENT AND SLOW ADOPTION
WHAT IS THE PROBLEM AND WHAT CAN WE DO?
Chairpersons: Dan Burkhoff (New York, NY, USA) & Faiez Zannad (CVCT, Paris, FRA)

Should devices always follow failure of comprehensive drug therapy?
Finn Gustafsson (Abbott, USA)

What is the development and adoption landscape?
Marat Fudim (Durham, NC, USA)

Can In-Silico Evidence Address the Device Development Bottleneck
Simon Sonntag (Virtonomy, GER)

Impediments and solutions to more sham control trials
Rita Redberg (San Francisco, CA, USA)

Why not more event driven trials? When and how
Robert Mentz (Durham, NC, USA)

Maximizing follow-up, Open Label Extension, and Real World Evidence
Maria Rosa Costanzo (Naperville, IL, USA)

Diuretic intensification and GDMT change – endpoints?
Javed Butler (Dallas, TX, USA)

PRO assessment, sham, blinding and placebo adjustment
Gregg Stone (New York, NY, USA)

Endpoints – hierarchical, Bayesian – what will work and what will be believe in?
Graeme Hickey (Medtronic, USA)

Industry Perspective
Philip Adamson (CVRx, USA), Navin Kapur (Abiomed/JnJ, USA), Faouzi Kallel (Berlin Heals, GER)

FDA Perspective
Ileana Pinea (FDA, USA)

Payers' viewpoints. The Device Evidence-to-Coverage Gap: Why Good Trials Do Not Guarantee Patient Access
JoAnna Baldwin (CMS, USA), Marco Marchetti (AGENAS, ITA)

Patient viewpoint
Corinne Hudson (Pumping Marvellous, GBR)

The CVCT Multi-Stakeholder Think Tank Moderated Debate

DEVICE THERAPIES FOR HEART FAILURE. SLOW DEVELOPMENT AND SLOW ADOPTION
WHAT IS THE PROBLEM AND WHAT CAN WE DO?
Chairpersons: Dan Burkhoff (New York, NY, USA) & Faiez Zannad (CVCT, Paris, FRA)

Panelists : Philip Adamson (CVRx, USA), JoAnna Baldwin (CMS, USA), Dan Burkhoff (New York, NY, USA), Javed Butler (Dallas, TX, USA), Maria Rosa Costanzo (Naperville, IL, USA), Andrew Farb (FDA, USA), Marat Fudim (Durham, NC, USA), Finn Gustafsson (Abbott, USA), Graeme Hickey (Medtronic, USA), Corinne Hudson (Pumping Marvellous, GBR), , Faouzi Kallel (Berlin Heals, GER), Navin Kapur (Abiomed/JnJ, USA), Marco Marchetti (AGENAS, ITA), Robert Mentz (Durham, NC, USA), Rhonda Monroe, (Charlotte, USA), Ileana Pinea (FDA, USA), Rita Redberg (San Francisco, CA, USA), Simon Sonntag (Virtonomy, GER), Gregg Stone (New York, NY, USA), Faiez Zannad (Paris, FRA)

East
Wednesday, December 9, 2026
14:30 -16:30

FROM EVIDENCE GENERATION TO UPTAKE
IMPLEMENTATION SCIENCE AND PAYMENT REFORM IN CARDIOMETABOLIC MEDICINE
Chairpersons: Ankeet S. Bhatt (San Francisco, CA, USA) & Neha Pagidipati (Durham, NC, USA)

Why positive CV trials still fail at uptake
Ankeet S. Bhatt (San Francisco, CA, USA)

Designing phase 3 trials for implementation from day 1
Harriette Van Spall (Hamilton, CAN)

Can pragmatic health-system trials help?
Tor Beiring Sorenson (Copenhague, DEN)

FDA's Total Life Cycle Advisory Program (TAP)
April Marrone (FDA, USA)

Implementation of science for equity in HF and cardiometabolic care
Mariam Elmegaard (Herlev, DEN),

Financial Toxicity
Karen Joynt Maddox (St. Louis, MO, USA)

Payment reform and New Models
Rishi Wadhera (Boston, MA, USA)

Payer/HTA perspective: coverage, affordability, and access after positive trials
Jaime Murillo (Bogotá, COL)

Industry Perspectives
Udi Fainberg (Novo Nordisk, DNK)

Patient Perspective
Steven Macari (AVEC, FRA)

The CVCT Multi-Stakeholder Think Tank Moderated Debate

IMPLEMENTATION-READY EVIDENCE GENERATION
Chairpersons: Ankeet S. Bhatt (San Francisco, CA, USA) & Neha Pagidipati (Durham, NC, USA)

Panelists : Ankeet S. Bhatt (San Francisco, CA, USA), Mariam Elmegaard (Herlev, DEN), Udi Fainberg (Novo Nordisk, DNK), Karen Joynt Maddox (St. Louis, MO, USA), Steven Macari (AVEC, FRA), April Marrone (FDA, USA), Jaime Murillo (Bogotá, COL), Neha Pagidipati (Durham, NC, USA), Tor Beiring Sørensen (Copenhagen, DNK), Harriette Van Spall (Hamilton, ON, CAN), Rishi Wadhera (Boston, MA, USA)

State
Wednesday, December 9, 2026
08:00 -10:00

CVCT-NIH/NHLBI joint session
THE TRIAL YOU DIDN'T KNOW YOU WERE RUNNING: IMPLEMENTATION PROBLEMS AS CARDIOVASCULAR SCIENCE
Chairpersons: Cara Lewis (NIH/NHLBI, USA) & Harriette Van Spall (Hamilton, CAN)

Some of the most consequential cardiovascular research of the past two decades didn't start with a molecule or a device — it started with a clock. When door-to-balloon time got attention, something deceptively radical occurred: treating the process of care delivery as a scientific problem worthy of rigorous investigation. The result was a body of evidence that changed how hospitals are organized, not just what drugs or devices they use.

This session invites cardiovascular trialists to look at their own work through the same lens: within or alongside the trials you are already running, what are the implementation problems hiding in plain sight?

Welcome and framing: What the clock taught us — the door-to-balloon story as a model for cardiovascular science
George Mensah (NIH/NHLBI, USA)

From trialist to implementation scientist: Rethinking what counts as a research question
Muthiah Vaduganathan (Boston, MA, USA)

The evidence-practice gap: When the evidence is sufficient, but the system is not
Christopher Granger (Durham, NC, USA)

Delivery as intervention: Designing trials around the prevention gap
Clara Chow (Syndney, AUS)

Where the gap is widest: Implementation science in low- and middle-income country cardiovascular care
Mohan Sailesh (New Delhi, IND)

The methodological toolkit: How to turn a care delivery problem into a rigorous trial
Mark Huffman (St Louis, MO, USA)

Journal Editors' Viewpoint: What journals need to see — making implementation science publishable in high-impact cardiovascular medicine
Flavia Geraldes (The Lancet, GBR)

Should implementation outcomes be co-primary endpoints in phase 3 cardiovascular trials?
Harriette Van Spall (Hamilton, CAN)

Who is responsible for closing the evidence-to-practice gap — trialists, health systems, regulators, or journals?
TBD

The CVCT Multi-Stakeholder Think Tank Moderated Debate
IF THE GAP BETWEEN EVIDENCE AND PRACTICE IS THE HIGHEST-YIELD TARGET IN CARDIOVASCULAR MEDICINE, WHAT IS STOPPING US?
Chairpersons: Cara Lewis (NIH/NHLBI, USA) & Harriette Van Spall (Hamilton, CAN)

Panelists : Michael Basson (Nature, USA), Clara Chow (Sydney, AUS), Anthony Etyang (Kilifi, KEN), Flavia Geraldes (The Lancet, GBR), Christopher Granger (Durham, NC, USA), Mark Huffman (St. Louis, MO, USA), Cara Lewis (NIH/NHLBI, USA), Steven Macari (AVEC, FRA), George Mensah (NIH/NHLBI, USA), Mohan Sailesh (New Delhi, IND), Muthiah Vaduganathan (Boston, MA, USA), Harriette van Spall (Hamilton, ON, CAN)

State
Wednesday, December 9, 2026
10:30 -13:30

WEARABLES IN CARDIOVASCULAR CLINICAL TRIALS: FROM SIGNAL TO ENDPOINT
Chairpersons: Jessilyn Dunn (Durham, NC, USA) & Abhinav Sharma (Montreal, CAN)

The 2025 CVCT wearables session ("Wearables for CV Trials") and AI Masterclass established that wearables are ready to participate in trials. The 2026 session advances the conversation by committing to a single, narrow question: how do we take a signal off a wrist and make it count as an endpoint? The structure is pipeline-based rather than stakeholder-based, and the case-study arc deliberately includes the one wearable-derived primary endpoint qualified anywhere in the world (SV95C in DMD) alongside a cardiovascular-adjacent pivotal trial that missed on a wearable endpoint (REBUILD). We explore the steps needed to bring wearables into larger scale clinical trials through multi-stakeholder discussions including understanding the impact of wearables on people with lived experience.

Setting the frame: from signal to endpoint in cardiovascular trials
Abhinav Sharma (Montreal, CAN)

Analytical validation: turning sensor signals into trustworthy digital measures
Jessilyn Dunn (Durham, NC, USA)

Clinical validation case studies: from measure to endpoint
Wearable activity monitoring in HF rehabilitation trials (REHAB-HF and beyond)
Ambarish Pandey (Dallas, TX, USA)

AFib burden
Jason Andrade (Vancouver, CAN)

Apple Heart & Movement Study
Calum Mac Rae (Boston, MA, USA)

Ambulatory / nocturnal BP– Cuffless devices
Paul Muntner (Birmingham, AL, USA)

Novel biomarkers: sleep, HRV, respiratory rate
Mintu Turakhia (Stanford, CA, USA)

REBUILD MVPA endpoint: lessons from a negative trial: Steven Nathan (Falls Church, VA, USA)

Safety monitoring: wearables as pharmacovigilance tools. Remote detection of decompensation and SAEs
Michael Gibson (Boston, MA, USA)

US Regulatory qualification pathways: Stephen Browning (FDA, USA)

Industry and CRO viewpoints
Punag Divanji (Cytokinetics, USA), Christine Guo (Ametris , USA) , Steven Lubitz (Novartis, USA),

NIH-NHLBI viewpoint: Yves Rosenberg (NIH, USA)

Regulatory viewpoint: Tariq Ahmad (FDA, USA)

Patient viewpoint: adherence, burden, and equity: Marc Bains (HeartLife, CAN)

The CVCT Multi-Stakeholder Think Tank Moderated Debate

WEARABLES IN CARDIOVASCULAR CLINICAL TRIALS. READY FOR MAINSTREAM?
Chairpersons: Jessilyn Dunn (Durham, NC, USA) & Abhinav Sharma (Montreal, CAN)

Panelists: Tariq Ahmad (FDA, USA), Jason Andrade (Vancouver, BC, CAN), Marc Bains (HeartLife, CAN), Juuso Blomster (CardioSignal, FIN), Stephen Browning (FDA, USA), Punag Divanji (Cytokinetics, USA), Jessilyn Dunn (Durham, NC, USA), Charu Gandotra (FDA, USA),Michael Gibson (Boston, MA, USA), Christine Guo (Ametris, USA), Steven Lubitz (Novartis, USA), Calum Mac Rae (Boston, MA, USA), Paul Muntner (Birmingham, AL, USA), Steven Nathan (Falls Church, VA, USA), Ambarish Pandey (Dallas, TX, USA), Yves Rosenberg (NIH, USA), Abhinav Sharma (Montreal, CAN), Mintu Turakhia (Stanford, CA, USA)

State
Wednesday, December 9, 2026
14:30 -16:30

DRIVERS OF HEART FAILURE: WHERE ARE WE?
Chairpersons: Lynne Warner Stevenson (Nashville, TN, USA) & Mark Petrie (Glasgow, GBR)

Overview of residual risk in heart failure.
Michele Senni (Bergamo, ITA)

Is pulmonary hypertension a treatment target in HFpEF?
Milton Packer (Dallas, TX, USA)

Hemodynamics as potential mechanistic target in pulmonary hypertension-related heart failure
Stuart Rich (Chicago, IL, USA)

Device therapy trials in pulmonary hypertension associated with left heart disease
Gegg Stone (New York, NY, USA)

Decompensated Heart Failure Trials. Where are we?
Jan Biegus (Wraclaw, POL)

Is there any value to singling out HFmrEF?
Gianluigi Savarese (Stockholm, SWE)

Racing the remodeling clock: Rapid-fire communications

Ghrelin for fast remodeling/recovery:
Lars Lund (Stockholm, SWE)

Fast full GDMT for fast remodeling/recovery
Alexandre Mebazaa (Paris, FRA)

Industry viewpoints
Mahesh Patel (Merck, USA), So Young Kim (Tenax, USA)

Regulatory viewpoints
Charu Gandotra (FDA, USA)

The CVCT Multi-Stakeholder Think Tank Moderated Debate

WHAT ARE THE NEXT HEART FAILURE TRIALS TARGET PATIENT POPULATIONS?
Chairpersons: Lynne Warner Stevenson (Nashville, TN, USA) & Mark Petrie (Glasgow, GBR)

Panelists: Jan Biegus (Wrocław, POL), Javed Butler (Dallas, TX, USA), Kieran Docherty (Glasgow, GBR), Charu Gandottra (FDA, USA), Josephine Harrington (Denver, COL), Riccardo inciardi (Brescia, IT), So Young Kim (Tenax, USA), Lars Lund (Stockholm, SWE), Alexandre Mebazaa (Paris, FRA), Rhonda Monroe, (Charlotte, USA), Rachel Neubrander (FDA, USA), Joanna Osmanska (Glasgow, UK), Milton Packer (Dallas, TX, USA), Mahesh Patel (Merck, USA), Mark Petrie (Glasgow, GBR), Stuart Rich (Chicago, IL, USA), Gianluigi Savarese Stockholm, SWE), Michele Senni (Bergamo, ITA), Gregg Stone (New York, NY, USA), Rhian Touyz (Montreal, CAN), Lynne Warner Stevenson (Nashville, TN, USA)

Chinese
Wednesday, December 9, 2026
10:30 -13:30

ESC-CVCT JOINT SESSION
LBCT 5
Hypertension, Obesity, and kidney disease
Chairpersons: Josephine Harrington (Aurora, CO, USA) & TBD

Session 1 (presentation times 8 min)

Carotid baroreceptor activation therapy vs. usual care in patients with resistant hypertension to four antihypertensive medications including spironolactone: a multicenter, open-label, blinded endpoint randomized controlled trial
P Rossignol1,*, M Azizi2,*, H Pereira2, JM Alsac2, G Chatellier2, F Zannad1
1Université de Lorraine - Nancy (France), 2Hopital Europeen Georges Pompidou, AP-HP - Paris (Monaco)

Sustained Remission of Primary Aldosteronism Two Years after an Extended Course of Adosterone Synthase Inhibition
MJ Brown, Frs1,*, AF Turcu, Md, Ms2, R Sam, Md3, LS Kirschner, Md, Phd4, O Hamidi, Do5, A Eren, Md4, A Ben-Shlomo, Md6, W Huang, Md7, I Bancos, Phd8, AH Hamrahian, Md9, MW Freeman, Md10
1Queen Mary University of London - London (United Kingdom), 2University of Michigan - Ann Arbor (United States), 3University of California - San Francisco (United States), 4Ohio State University Wexner Medical Center - Columbus (United States), 5University of Texas Southwestern Medical Center - Dallas (United States), 6Cedars-Sinai Health Sciences University - Los Angeles (United States), 7Northwestern University Feinberg School of Medicine - Chicago (United States), 8Mayo Clinic - Rochester (United States), 9Johns Hopkins University - Baltimore (United States), 10Harvard Medical School - Boston (United States)

Transform-HTN open label extension and embedded randomized treatment withdrawal trial: Long-term effects of lorundrostat, a novel aldosterone synthase inhibitor, in uncontrolled hypertension
M Saxena1,*, B Kopjar2, M Novin3, L Laffin4
1Barts Health NHS Trust and Queen Mary University - London (United Kingdom), 2University of Washington - Seattle (United States), 3Mineralys Therapeutics - Radnor (United States), 4Cleveland Clinic Foundation - Cleveland (United States)

Intensive blood pressure lowering in patients with diabetes: an individual participant data analysis of the OPTIMAL Program Implementation Trials
E Martins1,*, K Santo1, G S. Silva1, 2, P O. Guimarães1, C A.m. Tavares1, J Brainer1, 2, F Monfardini1, J Nieri1, S R.I. Assis1, R Nakagawa1, O Berwanger3, 4
1Hospital Israelita Albert Einstein - São Paulo (Brazil), 2Universidade Federal de São Paulo (UNIFESP), 3George Institute for Global Health UK - London (United Kingdom), 4Imperial College London

Participant Demographic Representation and Its Association with Primary Outcome Results and Downstream Impact of Major Cardiovascular Trials
B Bikdeli1,*, S Sina2, A Ashkan3, K Kushal4, S Syed5, P Pedro2, S Seng Chan6, Y Younwoo6, G Gregory2, D David7, R Roxana8, H Harlan9, G Gregg10
1BWH (United States), 2BWH - Boston (United States), 3UCSD - San Diego (United States), 4MGH - Boston (United States), 5Mayo Clinic - Scottsdale (United States), 6Yonsei University - Seoul (Korea, Republic of), 7Cardiovascular Research Foundation - New York (United States), 8Mount Sina Hospital - New York (United States), 9Yale University - New Haven (United States), 10Mount Sinai Hospital - New York (United States)

Discussant (10 min)
Anthony Rodgers (Sydney, AUS)

Q&A (10min)

Chinese
Wednesday, December 9, 2026
10:30 -13:30

ESC-CVCT JOINT SESSION
LBCT 5
Hypertension, Obesity, and kidney disease
Chairpersons: Josephine Harrington (Aurora, CO, USA) & TBD

Session 2 (presentation times 8 min)

Real-world Initiation, Persistence, and Target Trial Emulation of GLP-1 Receptor Agonist Therapy in Adults with Atherosclerotic Cardiovascular Disease and Overweight or Obesity
M Usman1,*, A Grewal2, J Moutchia-Suh3, K Patel4, N Keshvani3, M Khan5, K Nasir4, N Gossen6, A Ploumpis6, R Yang6, J Butler3, A Pandey2,*
1UT Southwestern Medical Center - Dallas (United States), 2University of Michigan - Ann Arbor (United States), 3Baylor Scott & White Research Institute - Dallas (United States), 4Houston Methodist Hospital - Houston (United States), 5Baylor Scott & White Health - Frisco (United States), 6Dandelion Health - Chappaqua (United States)

Expanding Evidence of Cardiovascular Outcomes Trials for Tirzepatide, Semaglutide, and Dulaglutide to Patients Without Atherosclerotic Cardiovascular Disease
N Dimpfl1, Y Kong1, M Adomi1, S Schneeweiss1, R Desai1, A Stephan1, H Schunkert2, S Wang1, N Krüger1,*
1Harvard Medical School, Brigham and Women's Hospital - Boston (United States), 2TUM University Hospital German Heart Center - Munich (Germany)

Prognostic enrichment beyond albuminuria for kidney outcome trials
B Neuen1,*, T Ferguson2, R Fletcher3, M Jardine1, K Tuttle4, V Vlado1, R Rajiv5, P Patrick6, A Alfredo6, N Niels7, D David3, G Glenn8, N Navdeep2, H Hiddo7
1 - Sydney (Australia), 2 - Winnepeg (Canada), 3 - London (United Kingdom), 4 - Spokane (United States), 5 - Indianapolis (United States), 6 - Berlin (Germany), 7 - Groningen (The Netherlands), 8 - Stanford (United States)

A Four-Category Definition of Worsening Renal Function Improves Prognostic Discrimination Beyond Binary Thresholds in Heart Failure With Reduced Ejection Fraction: An Individual Patient Data Analysis of EPHESUS, EMPHASIS-HF, and RALES
G Baudry1,*, P Rossignol2, L Monzo1, K Duarte1, K Damman3, A Voors3, B Pitt4, F Zannad1, N Girerd1
1Université de Lorraine, INSERM, Centre d'Investigation Clinique Plurithématique 1433, Inserm U1116, CHRU de Nancy and F-CRIN INI-CRCT, Nancy, France - Vandœuvre-lès-Nancy (France), 2Medical Specialties and Nephrology Departments, Princess Grace Hospital and M-CRIN, Monaco - Monaco (Monaco), 3Department of Cardiology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, Groningen 9713 GZ, The Netherlands - Groningen (The Netherlands), 4Department of Internal Medicine, University of Michigan Frankel Cardiovascular Center - Ann Arbor (United States)

Cardiovascular-Kidney-Liver-Metabolic Syndrome in Heart Failure with Reduced and Preserved Ejection Fraction
R Ono1,*, M Riccardi2, A Desai3, K Docherty1, A Henderson1, P Jhund1, L Køber4, M Komajda5, M Metra6, M Packer7, J Teerlink8, M Vaduganathan3, F Zannad9, M Zile10, S Solomon3, J Mcmurray1
1University of Glasgow - Glasgow (United Kingdom), 2ASST Cremona - Cremona (Italy), 3Brigham and Women's Hospital - Boston (United States), 4University of Copenhagen - Copenhagen (Denmark), 5Hospital Saint Joseph - Paris (France), 6Vita-Salute San Raffaele University - Milan (Italy), 7Baylor Heart and Vascular Institute - Dallas (United States), 8University of California San Francisco - San Francisco (United States), 9Université de Lorraine - Nancy (France), 10Ralph H. Johnson Veterans Affairs Medical Center and Medical University of South Carolina - Charleston (United States)

Discussant (10 min)
TBD

Q&A (10min)

Ballroom
Wednesday, December 9, 2026
08:00 -10:00

WHO IS IN THE COMMAND ROOM?
HOW BIG PHARMA, CROs, AROs AND REGULATORY BODIES ARE RESHAPING THE FUTURE OF CV INNOVATION.

Chairpersons : Robert Califf (Durham, NC, USA) & Martin Landray (Oxford, GBR)

Oncology, Device and rare disease have become the prototype ecosystem for accelerated innovation (surrogate endpoints, precision medicine, adaptive approvals, companion diagnostics, payer tolerance for uncertainty), whereas cardiovascular medicine remains more conservative, outcomes-driven, reimbursement-constrained, and operationally expensive. Has cardiovascular innovation become economically unviable? Are regulators slowing innovation — or protecting science? Did oncology “win” because it accepted uncertainty? Are heavy mega-trials now unsustainable?

Keynote lecture
How investors may help shift the Paradigm: Designing Trials for Ultra-Long-Acting and Permanent Adherence in Population-Scale CRM Disease»
Clive Meanwell (Population Health Partners, USA)

Why does oncology move faster than cardiovascular medicine?
Bonnie Ky (JACC Oncology, USA)

Are rare diseases the oncology-ization of cardiovascular medicine?
Sanjay Kaul (Los Angeles, CA, USA)
Jonathan Fox (BridgeBio, USA)

Why do cardiovascular devices and drugs follow different evidence pathways?
Roxana Mehran (New York, NY, USA)
Robert Califf (Durham, NC, USA)

Are we spending billions measuring things that no longer matter?
Martin Landray (Oxford, GBR)

Are clinical research organizations helping or hindering?
Milton Packer (Dallas, TX, USA)

The adjudication ritual: When is it really needed?
Hicham Skali (Boston, MA, USA)

The CVCT Multi-Stakeholder Think Tank Moderated Debate

HOW CAN BIG PHARMA, CROs, AROs AND REGULATORY BODIES ALIGN TO IMPROVE THE RATE OF CV DRUG INNOVATION?

Chairpersons : Robert Califf (Durham, NC, USA) & Martin Landray (Oxford, GBR)

Panelists : Robert Califf (Durham, NC, USA), Jonathan Fox (BridgeBio, USA), Sanjay Kaul (Los Angeles, CA, USA), Bonnie Ky (JACC Oncology, USA),,Martin Landray (Oxford, GBR), Roxana Mehran (New York, NY, USA), Milton Packer (Dalls, TX, USA), Rita Redberg (San Francisco, CA, USA), Tabassome Simon (Paris, FRA), Hicham Skali (Boston, MA, USA), Norman Stockbridge (Stockbridge LLC)

Ballroom
Wednesday, December 9, 2026
10:30 -13:30

PUBLISHING TRIAL RESULTS AND ADOPTION BY GUIDELINES. WHAT WOULD IT TAKE FOR JOURNALS AND GUIDELINES COMMITTEES TO NOT GIVE TRIALISTS A HARD TIME?

Chairpersons: Bradley Maron (Circulation, USA) & TBD

Editorial difficulties do not usually arise because journals want to be obstructive. They often arise because authors and journals approach the trial report with different priorities. Authors want to communicate the importance of the study; journals need to protect interpretability, proportionality, and trust. Guidelines are not simply a pass-through mechanism for positive trials or regulatory approvals. Guideline committees need to judge certainty, applicability, clinical priority, feasibility, and how new evidence fits within an existing therapeutic landscape.

Before the results: trial design choices that later determine editorial scrutiny.
Jan Tijssen (Brussels, BEL)
Endpoint hierarchy, composite outcomes, estimands, multiplicity, non-inferiority margins, subgroup plans, missing data, interim analyses, external validity, and whether the trial can answer the clinical question it claims to address.

After the results: how to report positive, neutral, or mixed findings avoiding interpretive tensions.
Sanjay Kaul (Los Angeles, CA, USA), Flavia Geraldes (The Lancet, GBR)
Discordant components of composite outcomes, positive secondary outcomes after neutral primary outcomes, underpowered safety findings, subgroup “signals”, effect sizes versus p values, and statistical versus clinical importance.

The editor/statistical reviewer perspective: what makes a trial paper easier or harder to accept?
Issa Dahabreh (JAMA, USA), Jane Leopold (NEJM, USA)
Protocol and SAP transparency, CONSORT adherence, completeness of reporting, sponsor role, data access, patient-relevant outcomes, and whether the interpretation is proportionate to the data.

Case Studies
•VICTOR a neutral primary outcome with an important mortality signal.
Faiez Zannad (Paris, FRA), Flavia Geraldes (The Lancet, GBR)

•SELECT a trial with a broad claim but narrow population
John Deanfield (London, GBR) , Jane Leopold (NEJM, USA)

When is one positive trial enough?
Ibrahim Halil Tanboga (Istanbul, TUR)
Strength of evidence, replication, internal validity, magnitude and consistency of benefit, patient-centred outcomes, safety, totality of evidence, and how committees think about class and level of recommendation.

From trial population to guideline population.
Tomasz Guzik (National Heart and Lung Institute, GBR)
Heart Failure guidelines: Applicability across sex, age, geography, comorbidity, kidney function, frailty, background therapy, under-represented groups, and whether subgroup evidence should narrow or broaden recommendations.

When evidence, approval, and guidelines move at different speeds.
Rita Redberg, San Francisco, CA, USA)
Conflicting trials, rapid therapeutic innovation, surrogate versus clinical outcomes, neutral or mixed trials, changing standards of care, and whether guidelines should lead, follow, or wait.

Case Studies
•BAROSTIM and BEAT-HF: Approved interventions without formal guideline recommendations
William Abraham (Columbus, OH, USA) , Bram Zuckerman (FDA, USA)

•PARTNER 3 plus NOTION-2. TAVR versus surgery: sequencing an irreversible intervention.
Michael Mack (Dallas, TX, USA) , Andrew Farb (FDA)
A class-effect question; a positive trial with limited generalizability; or a treatment whose uptake depends on sequencing with existing therapies.

Patients viewpoints
Rhonda Monroe (Charlotte, NC, USA)

The CVCT Multi-Stakeholder Think Tank Moderated Debate

PUBLISHING TRIAL RESULTS AND ADOPTION BY GUIDELINES. WHAT WOULD IT TAKE FOR JOURNALS AND GUIDELINES COMMITTEES TO NOT GIVE TRIALISTS A HARD TIME?

Chairpersons: Bradley Maron (Circulation, USA) & TBD

Panelists : William Abraham (Columbus, OH, USA), Issa Dahabreh (JAMA, USA), John Deanfield (London, UK), Andrew Farb (FDA, USA), Flavia Geraldes (The Lancet, UK), Tomasz Guzik (National Heart and Lung Institute, GBR), Sanjay Kaul (Los Angeles, CA, USA), Harlan Krumholz (JACC, USA), Jane Leopold (NEJM, USA), Michael Mack (Dallas, TX, USA), Bradley Maron (Circulation, USA), Rhonda Monroe (Charlotte, NC, USA), Ibrahim Halil Tanboga (Istanbul, TUR), Rita Redberg (San Francisco, CA, USA), Jan Tijssen (Brussels, BEL), Faiez Zannad (Paris, FRA), Bram Zuckerman (FDA, USA)

Ballroom
Wednesday, December 9, 2026
14:30 -16:30

THE MULTI-REGION REGULATORY HARMONIZATION MATRIX: PRAGMATIC REALITIES OF GLOBAL EVIDENCE ACCEPTANCE

Chairpersons: Robert M. Califf (Durham, NC, USA) & Clara Chow (Sydney, AUS)

The MHRA's Innovative Licensing and Access Pathway (ILAP): Accelerating Multi-Agency Scientific Alignment
Jacob George (MHRA, GBR)

The Mathematical Reality of ICH E17: How the FDA Evaluates Multi-Regional Clinical Trials (MRCTs)
Tzu-Yun.McDowell (FDA, USA)

Bridging the Atlantic: Friction and Successes within the EMA-FDA Parallel Scientific Advice Pipeline
Shannon Thor (FDA, USA)

Beyond Border Restrictions: The China's Evolution from Localized Phase 3 Trials to Global Multi-Center Trials
Clara Chow (Sydney, AUS)

One Global Trial, Multiple Regulatory Decisions: What Evidence Can Japan Accept—and What Still Needs to Be Local
Manabu Inoue (PDMA, JPN)

Erasing the «Drug Lag»: Operational Mechanics of Simultaneous Global Regulatory Submissions
Akihiro Ishiguro (PMDA, Tokyo, JPN)

How and where do Africa and other LMICs contribute?
Mpiko Ntsekhe (Cape Town, SA)
Habib Gamra (Sousse, TUN)
Zainab Dakhil (Baghdad, IRA)

Industry viewpoint
Charles Lee (AstraZeneca, USA)

Patient's viewpoints
Ratna Devi (DakshamA Health, IND)

The CVCT Multi-Stakeholder Think Tank Moderated Debate

«Friction & Alignment»: Navigating Conflicting Endpoint Requirements, Ethnic Sensitivity Bridging, and the Future of Sovereign Data Acceptance

Chairpersons: Robert M. Califf (Durham, NC, USA) & Clara Chow (Sydney, AUS)

Panelists: Stephen Browning (FDA, USA), Robert M. Califf (Durham, NC, USA), Clara Chow (Sydney, AUS), Zainab Dakhil (Baghdad, IRA), Ratna Devi (DakshamA Health, IND), Andrew Farb (FDA, USA), Habib Gamra (Sousse, TUN), Charu Gandotra (FDA, USA), Jacob George (MHRA, GBR), Manabu Inoue (PDMA, JPN), Akihiro Ishiguro (PMDA, Tokyo, JPN), Rob Kazmierski (MCRA, USA), Charles Lee (AstraZeneca, USA),Tzu-Yun.McDowell (FDA, USA), Karim Mikhail (FDA, USA), Mpiko Ntsekhe (Cape Town, SA), Chinwe Okoro (FDA, USA), Mitch Psotka (FDA, USA), Jon Resar (FDA, USA), Aliza Thompson (FDA, USA), Shannon Thor (FDA, USA), James Travis (FDA, USA), Changfu Wu (FDA, USA)